

Traumatic brain injury and peripheral immune suppression: primer and prospectus

Hazeldine, Jon; Lord, Janet M.; Belli, Antonio

DOI:

[10.3389/fneur.2015.00235](https://doi.org/10.3389/fneur.2015.00235)

License:

Creative Commons: Attribution (CC BY)

Document Version

Publisher's PDF, also known as Version of record

Citation for published version (Harvard):

Hazeldine, J, Lord, JM & Belli, A 2015, 'Traumatic brain injury and peripheral immune suppression: primer and prospectus', *Frontiers in neurology*, vol. 6, 235. <https://doi.org/10.3389/fneur.2015.00235>

[Link to publication on Research at Birmingham portal](#)

Publisher Rights Statement:

Eligibility for repository : checked 18/11/2015

General rights

Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes permitted by law.

- Users may freely distribute the URL that is used to identify this publication.
- Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private study or non-commercial research.
- User may use extracts from the document in line with the concept of 'fair dealing' under the Copyright, Designs and Patents Act 1988 (?)
- Users may not further distribute the material nor use it for the purposes of commercial gain.

Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.

When citing, please reference the published version.

Take down policy

While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been uploaded in error or has been deemed to be commercially or otherwise sensitive.

If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to the work immediately and investigate.



Traumatic brain injury and peripheral immune suppression: primer and prospectus

Jon Hazeldine^{1,2*}, Janet M. Lord^{1,2} and Antonio Belli^{1,2}

¹ NIHR Surgical Reconstruction and Microbiology Research Centre, Queen Elizabeth Hospital Birmingham, Birmingham, UK,

² Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK

OPEN ACCESS

Edited by:

Kenneth Curley,
US Army Medical Research and
Material Command, USA

Reviewed by:

Fredrik Clausen,
Uppsala University, Sweden
Firas H. Kobeissy,
University of Florida, USA

*Correspondence:

Jon Hazeldine
j.hazeldine@bham.ac.uk

Specialty section:

This article was submitted to
Neurotrauma, a section of the
journal *Frontiers in Neurology*

Received: 07 September 2015

Accepted: 23 October 2015

Published: 05 November 2015

Citation:

Hazeldine J, Lord JM and Belli A
(2015) Traumatic brain injury and
peripheral immune suppression:
primer and prospectus.
Front. Neurol. 6:235.
doi: 10.3389/fneur.2015.00235

Nosocomial infections are a common occurrence in patients following traumatic brain injury (TBI) and are associated with an increased risk of mortality, longer length of hospital stay, and poor neurological outcome. Systemic immune suppression arising as a direct result of injury to the central nervous system (CNS) is considered to be primarily responsible for this increased incidence of infection, a view strengthened by recent studies that have reported novel changes in the composition and function of the innate and adaptive arms of the immune system post-TBI. However, our knowledge of the mechanisms that underlie TBI-induced immune suppression is equivocal at best. Here, after summarizing our current understanding of the impact of TBI on peripheral immunity and discussing CNS-mediated regulation of immune function, we propose roles for a series of novel mechanisms in driving the immune suppression that is observed post-TBI. These mechanisms, which have never been considered before in the context of TBI-induced immune paresis, include the CNS-driven emergence into the circulation of myeloid-derived suppressor cells and suppressive neutrophil subsets, and the release from injured tissue of nuclear and mitochondria-derived damage associated molecular patterns. Moreover, in an effort to further our understanding of the mechanisms that underlie TBI-induced changes in immunity, we pose throughout the review a series of questions, which if answered would address a number of key issues, such as establishing whether manipulating peripheral immune function has potential as a future therapeutic strategy by which to treat and/or prevent infections in the hospitalized TBI patient.

Keywords: traumatic brain injury, immune system, immune suppression, infection

INTRODUCTION

Defined as “an alteration in brain function, or other evidence of brain pathology, caused by an external force” (1), traumatic brain injury (TBI) represents a major public health issue and socio-economic problem worldwide. An injury with multiple underlying etiologies, which include road traffic collisions, assaults, and falls, TBI was the primary diagnosis in 177,239 hospital admissions in England in 2013–2014 (2), while in the United States, an estimated 1.7 million people sustain a TBI annually, culminating in ~1.4 million emergency department visits, 275,000 hospitalizations and 52,000 fatalities (3).

The clinical impact of TBI is highlighted not only by its high mortality rate [TBI contributes to a third of all injury-related deaths in the United States (3)] but by the significant long-term health

complications reported by those who survive their injuries. Personality changes, anxiety, depression, short attention span, difficulty in information processing, as well as impaired coordination and balance are commonly reported by patients with non-fatal TBI, all of which pose significant challenges to their independent living, social reintegration, and working life (4, 5). Moreover, in addition to the physiological and psychological impact on the individual and their families, the effects of TBI extend to society as a whole. Across Europe in 2010, the economic cost of TBI was an estimated €33 billion (6), while in the United States, where around 5.3 million people are living with a TBI-related disability (7), the economic cost of TBI exceeds \$70 billion per year (8).

Hospital-acquired infections (HAIs) are a frequent occurrence in patients with severe TBI. As a result of colonization by such organisms as *Staphylococcus aureus* (*S. aureus*), *Pseudomonas aeruginosa*, and *Haemophilus influenza*, lower respiratory tract and surgical site infections are two of the most common non-neurological complications following severe TBI with an incidence rate of 24–72 and 17–25%, respectively (9–14). While it is currently unclear whether HAIs in TBI patients are associated with an increased risk of death (11, 15–19), numerous studies have demonstrated that HAIs result in significant patient morbidity. For instance, when compared to their non-infected counterparts, TBI patients with HAIs have significantly longer intensive care unit and hospital lengths of stay (11, 15, 17, 20), a greater degree of organ system dysfunction (11, 15), an increased duration of mechanical ventilation (11, 15, 20), and a worse neurological outcome at follow-up (14, 21). This detrimental effect of infection on neurological recovery has also been demonstrated in rodent trauma models, where in mild TBI, Venturi et al. (22) showed that the superimposition of sepsis resulted in a significant exacerbation of postinjury motor deficit and cognitive impairment as well as increased neuronal cell death in the hippocampus (22).

Multiple risk factors have been shown to be independently associated with the development of infections in hospitalized TBI patients. These include nasal carriage of *S. aureus* and barbiturate use (10), prolonged hospitalization, surgical intervention and cerebrospinal fluid leak (13), damage to the central nervous system (CNS), and the need for intubation and mechanical ventilation (12). Of these, it is injury to the CNS that is considered the main factor driving the increased susceptibility of TBI patients to HAIs. Mechanistically, this has been attributed to CNS injury disrupting the well-balanced bidirectional communication that exists between the CNS and the immune system, resulting in a state of systemic immune suppression (23). Indeed, *in vitro* and *in vivo* studies have shown significant changes occur in the number, phenotype, and function of cells belonging to both the innate and adaptive arms of the immune system post-TBI, a phenomenon termed CNS injury-induced immune deficiency syndrome (23).

In this article, we provide a comprehensive overview of the impact that TBI has on the circulating peripheral immune system and propose that alongside the well-described CNS-driven mechanisms of immune suppression, a series of novel immune-mediated mechanisms contribute to the altered immune function observed postbrain injury. Moreover, we highlight key areas of research that need to be tackled by future studies if we are to

gain a greater understanding of the mechanisms underlying TBI-induced changes in immunity and establish whether manipulation of the immune system could become a potential therapeutic avenue by which to treat the hospitalized TBI patient.

CURRENT UNDERSTANDING OF THE IMPACT OF TBI ON THE PERIPHERAL IMMUNE SYSTEM

Via a combination of historical observations (24–30) and results derived from recent experimental studies (31–38), it is evident that TBI has a significant impact on both the function and composition of the circulating immune cell pool. In this section, we provide a detailed description of the changes that have been reported to occur in both the innate and adaptive arms of the peripheral immune system following TBI, focusing predominantly on results obtained from human-based studies (Table 1). Given that very few of these studies have provided a mechanistic explanation for the changes they report, we make reference, where appropriate, to studies conducted in other fields of research whose results we believe offer plausible explanations for some aspects of immune dysfunction that have been reported post-TBI.

Innate Immunity Neutrophils

Armed with an array of microbicidal mechanisms, which include reactive oxygen species (ROS) generation and phagocytosis, neutrophils are the most abundant leukocyte in human circulation and the first immune cell to arrive at a site of pathogenic challenge. Following TBI, leukocytosis occurs, the result of profound neutrophilia. Both in the immediate aftermath of TBI as well as in the days following injury, studies have shown that relative to healthy control values, both the absolute number (34, 35, 39) and frequency (34, 39) of circulating neutrophils are significantly increased, with one study reporting a 4.5-fold elevation in neutrophil numbers as early as 3 h post-TBI (39). This immediate neutrophilia is thought to result from TBI-induced increases in serum catecholamines and glucocorticoids (33). A surge in catecholamines would trigger the entry of marginated neutrophils into the circulation, while a rise in glucocorticoid levels would increase the size of the peripheral neutrophil pool by stimulating their release from bone marrow stores and by extending their lifespan and preventing circulating neutrophils from returning to the bone marrow for clearance (33, 42). In terms of the neutrophilia that has been observed up to 48 h postinjury (39), Junger et al. (34) recently reported significantly fewer neutrophils isolated from TBI patients undergo spontaneous apoptosis during an overnight culture *in vitro* when compared to those from uninjured controls (34). Thus, a TBI-induced extension in neutrophil life-span may explain the elevated number of circulating neutrophils that have been reported in the days following injury.

In the immediate hours and days following mild, moderate, or severe TBI, neutrophils exhibit increased ROS generation, both in their resting state (35) as well as in response to stimulation with the bacterial peptide formyl-methionine-leucine-phenylalanine

TABLE 1 | Summary of TBI-induced changes in peripheral innate and adaptive immunity.

	Frequency/absolute numbers	Function	Reference
Neutrophils	Increased frequency and absolute number	Increased basal ROS generation	(39)
		Enhanced fMLP and PMA-induced ROS production in the acute phase of TBI	(34)
		Impaired ROS generation to <i>E. coli</i> stimulation at day 9 postinjury	(35)
		Reduced phagocytosis	(36)
Monocytes	Increased absolute number of total monocytes	Increased intracellular IL-10 expression	(30)
			(39)
	Increased absolute number of anti-inflammatory "M2" monocytes		(35)
Natural killer cells	Decreased frequency and absolute number of CD3 ⁺ NK cells	Increased percentage of perforin-positive CD3 ⁺ NK cells at day 1 postinjury	(40)
		CD56 ^{BRIGHT} NK cells at day 1 postinjury	
	Decreased frequency of CD56 ^{DIM} NK cells	Decreased percentage of perforin-positive CD3 ⁺ NK cells at day 4 postinjury	(41)
		CD56 ^{DIM} NK cells at day 4 postinjury	(31)
			(32)
T cells	Decreased percentage and absolute number of CD3 ⁺ , CD4 ⁺ , and CD8 ⁺ T cells	Decreased proliferation and cytokine production in response to PHA stimulation	(25, 27–29)
		Reduced LAK cytotoxicity	(40)
		Impaired DTH response	(41)
			(31)

DTH, delayed-type hypersensitivity; *E. coli*, *Escherichia coli*; fMLP, formyl-methionine-leucine-phenylalanine; IL, interleukin; LAK, lymphokine-activated killer; PHA, phytohemagglutinin; PMA, phorbol 12-myristate 13-acetate; ROS, reactive oxygen species; TBI, traumatic brain injury.

(fMLP) and the protein kinase C activator phorbol 12-myristate 13-acetate (PMA) (34). In a recent study, Liao et al. attributed the enhancement in basal ROS generation to a TBI-induced increase in gp91^{phox} (35). The heme binding subunit of the ROS generating enzyme nicotinamide adenine dinucleotide phosphate (NADPH) oxidase (43), Liao et al. found gp91^{phox} expression was significantly higher in leukocytes isolated from TBI patients within 24 h of their injury when compared to leukocytes from uninjured controls (35). Interestingly, besides healthy controls, neutrophils from TBI patients generated significantly more ROS at rest and expressed higher amounts of gp91^{phox} than neutrophils obtained from patients that had suffered general trauma with no CNS injury (35), suggesting that TBI initiates a more robust oxidative response than non-head trauma. While the mechanism(s) underlying this exaggerated response are currently unknown, the loss of regulatory feedback control on immune function as a result of direct CNS injury has been proposed as one potential explanation (35).

In contrast to the enhanced ROS generation that characterizes the initial response to TBI (34, 35), neutrophils exhibit impaired ROS generation in the days following injury (36, 40). In a study of hospitalized TBI patients with moderate or severe brain trauma, Marks et al. (36) found that neutrophil ROS production on day 9 postinjury was significantly lower than that of healthy age- and sex-matched controls. Given that peak incidences of infection in hospitalized TBI patients occur 5–11 days after injury (21, 36), and neutrophils are the first line of defense against rapidly dividing bacteria, fungi, and yeast; then impaired ROS generation may be one mechanism underlying the increased susceptibility of hospitalized TBI patients to infection. With this in mind, a comparison of ROS generation between neutrophils isolated from non-infected and infected TBI patients revealed a significantly greater percentage of ROS producing cells in the uninfected group on day 6 postinjury (36).

Following TBI, the ability of circulating neutrophils to phagocytose immunoglobulin and complement-coated *Escherichia coli* (*E. coli*) is significantly reduced (35, 36). This impairment, which has been observed in the hours (35), days (35, 36), and weeks (35) following injury relates to both the percentage of phagocytosing cells as well as their individual cellular activity (number of *E. coli* engulfed per cell). The reduction in phagocytosis that occurs post-TBI is significantly greater than that which occurs following general trauma with no CNS injury (35) and has been suggested to reflect a compensatory mechanism aimed at minimizing the deleterious effects of the afore-mentioned TBI-induced increase in neutrophil ROS generation (35). In the setting of critical illness, a reduction in neutrophil phagocytosis akin to that observed following TBI has been reported in patients with suspected ventilator-associated pneumonia (44), an impairment that has been attributed to activation of the complement system (44, 45). More specifically, it has been shown that by activating the delta isoform of phosphoinositide 3-kinase, the complement component C5a inhibits the Rho GTPase RhoA, which is the key mediator of the actin polymerization that is required for neutrophils to engulf complement-coated pathogens (45, 46). While it is currently unknown as to whether *in vivo* exposure to C5a mediates the reduced uptake of complement-coated *E. coli* by neutrophils post-TBI, this is a mechanism worth investigating given that complement activation is a feature of the inflammatory response to TBI (47, 48) and in a murine model of TBI, C5a was found to influence the functional behavior of circulating neutrophils (49).

Monocytes

Monocytes are a heterogeneous population of blood-borne leukocytes that comprise ~5–10% of the circulating immune cell pool and based on the differential surface expression of CD14 and the Fc receptor CD16 are categorized into one of three distinct

subsets: classical (CD14⁺⁺16⁻), non-classical (CD14⁺16⁺⁺), or intermediate (CD14⁺⁺16⁺) (50). Currently, there is a paucity of information on what effect TBI has on monocyte biology, with a small number of groups focusing upon changes in their number, surface phenotype, and cytokine production.

In contrast to murine-based studies, where significant reductions in monocyte number have been observed in the early hours and days following TBI (37), human studies have shown that TBI leads to a significant elevation in the absolute number of circulating monocytes (35, 39). Whether this increase in monocytes, whose numbers in one study were 2.7-fold higher relative to healthy controls within 24 h of injury (35), is the result of an increase in all monocytes or reflects the expansion of specific subsets which is currently unknown. However, changes that have been described in the surface phenotype of circulating monocytes post-TBI suggest that the latter is responsible. The selectin CD62L, which mediates initial tethering and rolling of marginated cells along the vessel wall, is expressed exclusively on CD14⁺⁺16⁻ classical monocytes (51, 52), while the β_2 -integrin CD11b is present in greater amounts on the surface of both classical and intermediate monocyte subsets than on non-classical monocytes (52). Following TBI, analysis of the monocyte pool in its entirety has revealed significant increases in CD11b and CD62L surface density (39). Given the expression profiles of these two adhesion markers, this data suggests that it is expansion of both the classical and intermediate subsets that drives the significant elevation in monocyte number observed post-TBI (35, 39).

In addition to surface phenotype, monocytes can be categorized into distinct subsets based upon their inflammatory properties and maturation profiles. In mice, Ly6C⁺ classical monocytes secrete proinflammatory cytokines and following entry into tissue mature into inflammatory M1 macrophages, while Ly6C⁻ non-classical monocytes secrete the anti-inflammatory cytokine IL-10 and differentiate into anti-inflammatory M2 macrophages (53). In a murine model of closed head injury, Schwulst et al. (37) found a significantly greater number of anti-inflammatory Ly6C⁻ monocytes in the peripheral circulation of TBI mice at 60 days postinjury when compared to sham controls, suggesting that TBI results in a shift toward an anti-inflammatory monocyte pool (37). In line with this observation, intracellular expression of IL-10 has been detected in monocytes isolated from human TBI patients immediately after injury (30), suggesting that akin to the situation described in mice, TBI in humans elicits an anti-inflammatory response in circulating monocytes.

Natural Killer Cells

Phenotypically defined as CD3⁻56⁺, natural killer (NK) cells are large granular lymphocytes renowned for their role in the recognition and elimination of virally infected, malignant, and transformed cells. In the days (31, 38) and weeks (38) following mild (38), moderate (38), and severe (31, 38) TBI, significant reductions have been reported in the absolute number and frequency of circulating NK cells. These measures correlated positively with both the Glasgow coma scale (GCS) score, suggesting that the changes observed could be a direct consequence of the brain injury (31, 38), and the Glasgow outcome scale (GOS),

suggesting a relationship between immune status and physiological recovery (38). Based on the differential surface expression of CD56, NK cells can be categorized into two major subsets, namely cytotoxic CD56^{DIM} NK cells and immunoregulatory CD56^{BRIGHT} NK cells. Following TBI, the frequency of CD56^{DIM} but not CD56^{BRIGHT} NK cells is significantly diminished (31), indicating that it is a specific reduction in the CD56^{DIM} subset that is responsible for the above-mentioned decline in the total (CD3⁻56⁺) NK cell pool.

While it is currently unclear as to why TBI results in a significant decline in the number of circulating NK cells, one school of thought is that it represents a mechanism by which to prevent autoimmunity and CNS inflammation (38). *In vitro*, NK cells have been shown to kill resting microglia (54), the resident macrophage-like cell of the CNS that upon activation produces proinflammatory cytokines and acquires the ability to process and present antigens to CNS infiltrating T cells (55). Furthermore, it has been shown *in vivo* that CNS residing NK cells suppress the microglia-mediated induction of proinflammatory T helper 17 cells (56, 57). Thus, it has been proposed that the reduction in circulating NK cell numbers post-TBI is the result of NK cells entering the brain via the damaged blood-brain barrier, where through influencing microglial number and function they prevent the amplification of inflammatory processes and thus bystander damage in the CNS (38). An alternative mechanism that could explain the decline in circulating NK cell numbers post-TBI is cell death. As reported for other lymphocytes, glucocorticoid treatment *in vitro* has been shown to induce apoptosis in resting NK cells (58, 59). Thus, it is conceivable that the increase in serum glucocorticoids that accompanies TBI could trigger the induction of programmed cell death in circulating NK cells, culminating in a significantly reduced peripheral pool.

NK cells eliminate transformed cells primarily via the granule exocytosis pathway, a contact-dependent mechanism of defense that involves the directed secretion of the pore-forming protein perforin onto the target cell surface. Within 24 h of severe TBI, significant increases have been reported in the percentage of perforin-positive CD3⁻CD56⁺, CD56^{DIM} and CD56^{BRIGHT} NK cells (32). As perforin expression is enhanced by proinflammatory cytokines (60), this increase in perforin positive NK cells has been proposed to be due to the leakage of interleukin (IL)-1, IL-6, and tumor necrosis factor-alpha (TNF- α) from the CNS into the circulation (32). Interestingly, by day 4 post-TBI, a time-point where the frequency of perforin-positive CD3⁻CD56⁺ NK cells correlates positively with GCS score, the percentage of perforin-positive CD3⁻CD56⁺ and CD56^{DIM} NK cells is significantly reduced relative to healthy controls (32), a decline that may contribute to the increased susceptibility of the hospitalized TBI patient to infection.

Adaptive Immunity

Until recently, TBI was thought to have no impact upon B-cell biology, a belief based upon a handful of studies that had shown no alterations in the frequency, absolute number, or proliferative capacity of B cells following severe TBI (24, 28, 31, 40, 61). However, in two recent studies, autoantibodies specific for CNS

proteins were detected in the serum of TBI patients, suggesting that following TBI, self-tolerance is broken and B cells initiate an immune response against brain-derived antigens. In the setting of mild TBI, Marchi et al. found that serum levels of the astrocytic protein S100B were higher in subjects that had experienced frequent sub-concussive head hits (SHH) and that the presence of this protein was accompanied by an elevation in anti-S100B autoantibodies (62). As raised S100B autoantibody levels were associated with poor performance in cognitive tests, and these autoantibodies reacted strongly toward both glial and neuronal cell epitopes, it was hypothesized that the generation of autoantibodies against CNS-residing proteins may represent a risk factor for premature neurodegeneration in individuals who suffer repeated SHH (62). In line with these observations, Zhang et al. detected autoantibodies against the astrocyte-residing intermediate filament protein glial fibrillary acidic protein (GFAP) and its breakdown products in serum samples obtained from 53 patients following severe TBI (63). These GFAP autoantibodies, which were detected as early as 4 days postinjury and whose levels positively correlated with GCS scores, were shown to induce glial cell injury *in vitro*, suggesting a potential pathophysiological role for B cells during the recovery phase of TBI (63).

Severe TBI results in a significant decrease in the percentage and absolute number of circulating T lymphocytes (31, 40, 41). This decrease, which has been observed within 24 h of injury (31, 41) as well as on day 4 postinjury (31), is the result of a significant reduction in both CD4⁺ T helper cells and CD8⁺ cytotoxic T cells (31, 40, 41). Currently, the mechanism(s) underlying this TBI-induced shrinkage of the circulating T-cell pool is unclear although results of a recent murine-based study offer a potential explanation. In a series of *in vivo* experiments, Nakai et al. (64) found that administration of B₂-adrenergic receptor (B₂AR) agonists resulted in a rapid reduction in the numbers of blood CD4⁺ and CD8⁺ T cells, with further investigations revealing this lymphopenia was the result of B₂AR stimulation inhibiting lymphocyte egress from lymph nodes (64). Given that TBI results in increased circulating levels of catecholamines (65, 66), then lymphocyte retention in lymph nodes may be one mechanism by which to explain the significant reduction in circulating T cells that has been observed following TBI.

Alongside numerical changes, a multitude of functional defects have been reported in circulating T cells following TBI. While *in vitro* studies have shown that T cells isolated from patients with severe TBI exhibit reduced proliferation and cytokine production following phytohemagglutinin stimulation (26–28) as well as impaired lymphokine-activated killer (LAK) cytotoxicity following incubation with IL-2 (26, 27, 29), *in vivo* studies have revealed severe TBI results in suppressed delayed-type hypersensitivity (DTH) skin test responses to a range of antigens, which include *Candida*, mumps, and trichophyton (25, 28, 61). Mechanistically, this reduction in cell-mediated immunity has been suggested to be due to serum factors with immune-suppressive activity (29, 61) and the presence of suppressor lymphocytes that actively inhibit effector lymphocyte function (29).

NEURAL REGULATION OF THE IMMUNE RESPONSE

Critical for the regulation of peripheral inflammatory responses is the bidirectional communication that exists between the immune system and the CNS. The brain senses peripheral inflammation via two main pathways; a neural pathway, which involves activation of the afferent sensory fibers of the vagus nerve, and a humoral pathway, in which circulating cytokines signal to the brain either by crossing the blood–brain barrier or by binding their cognate receptors on the brain microvasculature (67, 68). Interestingly, a functional lymphatic system within the CNS has recently been discovered, suggesting an additional level of communication between the CNS and the immune system (69, 70). Of particular interest with regards to TBI, Louveau showed B cells, T cells, and dendritic cells reside in meningeal lymphatic vessels and that these vessels serve as the primary route for the drainage of cerebrospinal fluid (CSF)-derived soluble and cellular constituents into cervical lymph nodes (CLNs) (70). Given that the contents of CSF have been shown to trigger immune responses in CLNs (71), this CNS lymphatic system may represent a novel means by which the immune system could detect alterations in brain physiology post-TBI.

Having sensed peripheral inflammation, the brain, in an effort to restore immune homeostasis, responds by signaling to the immune system via three immunomodulatory pathways: (1) the hypothalamic–pituitary–adrenal (HPA) axis (2) the sympathetic nervous system (SNS), and (3) the parasympathetic nervous system (PNS). In the context of TBI and peripheral immune suppression, the direct injury to the brain and/or the resulting ischemia, raised intracranial pressure and cerebral cytokine production that develops in the days and weeks postinjury is thought to disrupt the well-balanced interplay between the immune system and the CNS. Activation of the above-mentioned pathways of neural immune modulation in the absence of a peripheral inflammatory response culminates in a state of systemic immune depression that is thought to increase the risk of the TBI patient to nosocomial infection. Here, we provide a brief overview of the three above-mentioned neural pathways of immune modulation, highlighting key studies whose results suggest that these pathways may play a prominent role in mediating TBI-induced immune suppression.

The Hypothalamic–Pituitary–Adrenal Axis

The HPA axis represents the primary hormonal pathway through which the CNS regulates peripheral immune function. Glucocorticoids, the main effector hormone of the HPA axis, modulate immune cell functions via binding to the glucocorticoid receptor, a cytosol residing ligand-dependent transcription factor, which modulates the expression of genes involved in cytokine production and such immune responses as cell trafficking and phagocytosis (72).

Via a series of mechanisms, which range from the destabilization of mRNA to inhibiting the binding of transcription factors to DNA (73), glucocorticoids suppress the production of several proinflammatory cytokines and inflammatory mediators, which

include IL-1 β , IL-6, IL-12, TNF- α , IFN- γ , nitric oxide, and prostaglandins (74–76). In contrast, glucocorticoids promote the secretion of the anti-inflammatory cytokines IL-4 and IL-10 (75). Through this modulation of inflammatory cytokine production, glucocorticoids effect immune cell trafficking by suppressing TNF- α -mediated increases in endothelial cell surface adhesion molecules (77) and influence T-cell biology by driving the differentiation of naive T lymphocytes to T helper 2 (T_H2) cells and blocking T_H1 development (78, 79).

In terms of their effects on immune cell function, glucocorticoids have been found to increase the T-cell-suppressive capacity of anti-inflammatory “M2” macrophages (80), suppress the cytotoxicity activity of NK cells by decreasing expression of the pore-forming protein perforin (81), inhibit neutrophil phagocytosis (82), induce lymphocyte apoptosis (83), and influence the antigen-presenting capacity of monocytes and dendritic cells by downregulating their expression of MHC class II and the costimulatory molecule CD86 (84, 85).

The Sympathetic Nervous System

Through extensive innervation of primary (bone marrow and thymus) and secondary (lymph nodes and spleen) lymphoid organs and the expression of α and β adrenergic receptors on the surface of almost all circulating leukocytes, the SNS elicits a strong regulatory influence on peripheral immune function (86). In a series of *in vitro* experiments, catecholamines, the effector neurotransmitter of the SNS, or their pharmacological analogs have been shown to suppress, in a β -adrenergic receptor-dependent manner, a range of immune functions, which include neutrophil ROS generation, inflammatory cytokine production, and NK-cell cytotoxicity (86–91). With respect to cytokine production, pretreatment of whole blood or isolated monocytes, macrophages, or dendritic cells with epinephrine, norepinephrine, or the β_2 -agonist salbutamol has been found to significantly inhibit lipopolysaccharide (LPS)-induced IL-12 and TNF- α secretion (88, 89, 91, 92), a suppression that in the case of IL-12 was associated with an increase in intracellular cyclic adenosine monophosphate levels (92). While inhibiting proinflammatory cytokine production, catecholamines enhance the generation of anti-inflammatory cytokines, with epinephrine and norepinephrine treatment of whole blood or isolated monocytes significantly increasing both basal and LPS-induced secretion of IL-10 (88, 89, 93). Via these effects on inflammatory cytokine production, β -adrenergic receptor stimulation has been shown to indirectly influence the differentiation of naive T cells, promoting the development of T_H2 cells and inhibiting the generation of T_H1 cells (92). Given that TBI results in elevated circulating levels of catecholamines (65, 66), this catecholamine-induced shift in the T_H1/T_H2 balance in favor of anti-inflammatory T_H2 cells may be one factor behind the increased susceptibility of TBI patients to infection.

In line with the *in vitro* effects of catecholamines, human- and murine-based *ex vivo* studies have demonstrated in a number of experimental settings an immune suppressive role for the SNS (90, 93–95), which in the case of direct CNS injury has been linked to the development of infection. In a murine model of stroke, Prass et al. found that inhibition of the SNS immediately

following the onset of cerebral ischemia improved survival rates by preventing the spontaneous development of systemic bacterial infections that was observed in control mice (95). Underlying this protective effect was an enhanced immune response with *ex vivo* experiments, revealing that inhibition of the SNS prevented a stroke-induced reduction in IFN- γ production by circulating T lymphocytes; a function that the group found was crucial in controlling bacterial infections' poststroke (95).

Both prospective and retrospective cohort studies have shown that the use of β -adrenergic receptor antagonists in adult TBI patients is independently associated with improved survival (96–98). Given that a reduced risk of ischemia, enhanced brain tissue metabolism and oxygen consumption as well as protection of the cardiovascular system are all potential benefits of this treatment protocol (98–101), it is likely that alterations to a number of physiological processes underlie this protective effect of β -adrenergic receptor blockade on patient survival post-TBI. However, *could reducing the incidence of infection by preventing SNS-induced immune suppression be an additional underlying mechanism?* This hypothesis has been rebuffed by some groups who reported a higher incidence of infectious complications among TBI patients treated with β -adrenergic receptor antagonists (97, 102). However, in these studies, patients who underwent this treatment protocol were older, more-severely injured and received a higher number of blood transfusions than their untreated counterparts (97, 102). Moreover, in one study, many of the patients did not commence their therapy until after the diagnosis of infection (97). Thus, to answer this question correctly, a study that performs β -adrenergic receptor blockade in a randomized, double-blinded, placebo-controlled trial of appropriately matched TBI patients that measures immune function, infection incidence, and outcome is required. Results of such a study would go a long way to addressing whether in the clinical setting of TBI, the surge in circulating catecholamines is causally linked to the subsequent development of immune suppression, and if so what impact this has on patient outcome.

The Parasympathetic Nervous System

In a landmark study in 2000, Borovikova et al. described for the first time a vagus nerve-mediated parasympathetic pathway of immune modulation. After showing *in vitro* that treating primary human macrophage cultures with acetylcholine (ACh), the principal parasympathetic neurotransmitter significantly inhibited LPS-induced secretion of TNF- α , IL1- β , IL-6, and IL-18 without affecting the production of the anti-inflammatory cytokine IL-10, the group demonstrated *in vivo* a role for parasympathetic signaling in regulating systemic inflammatory responses (103). In a rat model of lethal endotoxemia, electrical stimulation of the efferent vagus nerve (which increases ACh release) significantly reduced serum TNF- α levels, whereas in mice subjected to vagotomy without electrical stimulation, TNF- α levels were significantly increased when compared to sham-operated controls (103). These two novel findings were the first to directly implicate efferent vagus nerve signaling in the regulation of proinflammatory cytokine production *in vivo*. Termed the cholinergic “anti-inflammatory” pathway, this neural mechanism of immune

modulation is rapid, discrete, and localized when compared to the diffusible anti-inflammatory network (e.g., glucocorticoids and anti-inflammatory cytokines), therefore allowing for “real time” regulation of immune responses (103, 104).

As well as exerting anti-inflammatory effects in models of systemic inflammation such as severe sepsis (105, 106), haemorrhagic shock (107), and ischemia/reperfusion (108), a role for parasympathetic signaling in regulating localized peripheral inflammatory responses has been reported. In an experimental model of carrageenan-induced paw edema, electrical stimulation of the vagal nerve or local administration of ACh significantly attenuated the development of acute inflammation (109), an outcome that may be explained by the ability of ACh to inhibit endothelial cell activation and leukocyte recruitment (110).

The essential signaling component that links ACh release from efferent vagal fibers to peripheral immune suppression is the $\alpha 7$ subunit of the nicotinic ACh receptor (106, 111). *In vitro* treatment of human macrophages with antisense oligonucleotides specific for the $\alpha 7$ subunit has been shown to restore TNF- α secretion upon nicotine stimulation (111), while peritoneal macrophages isolated from $\alpha 7$ subunit deficient mice were found to be refractory to cholinergic agonists, secreting significantly greater amounts of TNF- α following LPS stimulation in the presence of ACh or nicotine when compared to macrophages from control mice (111). Moreover, *in vivo* studies have reported elevated serum levels of TNF- α , IL1- β , and IL-6 in $\alpha 7$ -subunit-deficient mice after endotoxin challenge and shown that electrical stimulation of the vagus nerve in these mice fails to reduce this proinflammatory response (111).

Based on the results of the afore-mentioned studies and clinical data suggesting TBI results in enhanced parasympathetic activity (112), it has been hypothesized that overactivity of the vagus nerve may be responsible, at least in part, for the peripheral immune suppression that is observed following TBI (113, 114). An increase in vagal tone would occur as either a direct consequence of the TBI or as a result of elevated intracranial pressure, leading to systemic immune suppression that increases the susceptibility of the hospitalized TBI patient to infection (113, 114). Although plausible, it must be noted that no clinical studies have been performed to date that have investigated a role for parasympathetic signaling in mediating the increased incidence of infection in TBI patients. That said, if this theory is proven to be correct then modulating the activity of the vagus nerve could be a novel therapeutic approach by which to reduce not only the direct mortality attributable to infection but also the long-term effects of infection in respect to poor neurological outcome in TBI patients (113, 114).

NEW CONCEPTS IN TBI-INDUCED IMMUNE SUPPRESSION


In spite of the recent increase in the number of studies that have investigated the effect of TBI on peripheral immunity (31, 32, 34–39), only one has provided a mechanistic explanation for their findings (35), with the majority merely reporting functional impairments relative to healthy controls (31, 32, 36, 37). This paucity of information on the mechanisms that

underlie TBI-induced changes in immunity represents a major barrier that needs to be overcome if novel immune-based therapeutic strategies aimed at reducing the incidence of nosocomial infection in hospitalized TBI patients are to be developed. While disruption of the well-balanced interplay that exists between the nervous system and the immune system clearly plays a key role in TBI-induced immune suppression (23), it is likely that additional mechanisms are involved. In other forms of traumatic injury, non-neurological mechanisms of immune suppression have recently been described, with *in vitro*, *in vivo*, and *ex vivo* data revealing trauma results in the emergence into the circulation of suppressive immune cell subsets and damage-associated molecular patterns (DAMPs), with exposure to the latter inducing tolerance in peripheral immune cells (115–119). In this section, we discuss these recent studies, relate their findings to TBI and propose that that the presence of suppressive immune cells and DAMPs in the circulation contributes to the immune suppression that is observed following TBI (Figure 1).

Myeloid-Derived Suppressor Cells as Mediators of *In Vitro* and *In Vivo* T-Cell Dysfunction Post-TBI

Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells consisting of myeloid progenitors and precursors of granulocytes, macrophages, and dendritic cells. First described in the field of cancer research and characterized since in a number of pathological conditions such as sepsis, autoimmunity, and trauma, MDSCs are potent suppressors of T-cell function (120, 121). Via the production of ROS and reactive nitrogen species, expression of arginase 1, and secretion of immunosuppressive cytokines, MDSCs inhibit T-cell proliferation, promote T-cell apoptosis, block translation of the T-cell CD3 ζ chain, and mediate expansion of CD4⁺CD25⁺FoxP3⁺ regulatory T cells (120, 121).

In murine models of trauma (122) and chronic physiological stress (123), endogenous GCs and catecholamines have recently been shown to promote the expansion and accumulation of MDSCs. Thus, if we assume that akin to other forms of traumatic injury (115, 116), the initial act of brain injury is sufficient to cause MDSC release from the bone marrow then the increased serum levels of GCs and catecholamines found in TBI patients is an environment that favors MDSC proliferation and expansion. Consequently, it is not inconceivable that the presence of MDSCs in circulation could be one mechanism underlying the profound *in vivo* and *in vitro* T-cell suppression that occurs following TBI (25–28, 61). In fact, this scenario may have already been described. In a study published prior to the discovery of MDSCs, Quattrocchi et al. (29) found that when cocultured with lymphocytes isolated from patients with severe TBI, peripheral blood mononuclear cells (PBMCs) from healthy controls exhibited significantly reduced LAK cytotoxicity, suggesting the presence of suppressor lymphocytes in TBI patients (29). Interestingly, when performing standard PBMC isolation protocols using Ficoll-Hypaque density gradient centrifugation, MDSCs due to their reduced buoyant density reside in the same layer as lymphocytes (124). Thus, it may be that the lymphocytes isolated from TBI patients



by Quattrocchi et al. (29) were contaminated with MDSCs and that it was these cells that were responsible for the reduction in T-cell cytotoxicity they reported.

Recently, MDSCs have been touted as a therapeutic target in the treatment of cancer with strategies aimed at either (1) deactivating MDSCs, (2) blocking their development, or (3) driving

their differentiation into mature cells all currently under clinical investigation (125). If through future research, MDSCs are found to play a role in TBI-induced immune dysfunction then similar approaches may be worth considering as a potential therapeutic avenue for the treatment of nosocomial infections in the hospitalized TBI patient.

Suppressive CD16^{BRIGHT} CD62L^{DIM} Neutrophils and CD16^{DIM} Immature Granulocytes as Potential Mediators of *In Vivo* T-Cell Dysfunction Post-TBI

Historically, neutrophils have been considered a relatively homogeneous cell population. However, in recent years it has become apparent that in times of severe systemic inflammation, distinct neutrophil subsets emerge into the circulation. Based on the differential surface expression of the Fc receptor CD16 and the adhesion molecule L-selectin, three distinct neutrophil subsets, defined as CD16^{DIM} CD62L^{BRIGHT}, CD16^{BRIGHT} CD62L^{DIM}, or CD16^{BRIGHT} CD62L^{BRIGHT} have been identified in severely injured patients (118). CD16^{BRIGHT} CD62L^{DIM} neutrophils have been shown *in vitro* to potently suppress T-cell proliferation via a Mac-1-dependent mechanism that involves the release of hydrogen peroxide into the immunological synapse that forms between CD16^{BRIGHT} CD62L^{DIM} neutrophils and T cells (118). Importantly, CD16^{BRIGHT} CD62L^{DIM} neutrophils are a subset of mature neutrophils, thereby distinguishing them from the above-mentioned immature MDSCs who also suppress T-cell function (118). Currently, it is unknown as to whether suppressive CD16^{BRIGHT} CD62L^{DIM} neutrophils form part of the expanded peripheral neutrophil pool that is observed following TBI, although one study in patients with severe TBI recently reported a significant reduction in both CD62L surface density and the percentage of CD62L⁺ neutrophils, suggesting that suppressive neutrophils may be released into the circulation post-TBI (34). Hypothetically, their presence may be one explanation for the suppressed DTH skin test responses elicited by patients with severe TBI (25, 28, 61).

CD16^{DIM} neutrophils possess a “young” banded morphology, suggesting that these cells are immature granulocytic precursors (118). In a recent study of patients with septic shock, a subset of immature granulocytes (IGs) phenotypically defined as CD16^{DIM} 14⁺ 24⁺ were described and shown *in vitro* to elicit potent cytotoxicity against CD3⁺ lymphocytes (126). Interestingly, in these patients, a marked excess of CD16^{DIM} IGs was found to be significantly associated with both CD3⁺ and CD4⁺ T-cell lymphopenia (126). On this note, a feature of the acute immune response to severe TBI is a significant increase in circulating IG numbers (33), whose elevation precedes the well-described CD3 and CD4 T-cell lymphopenia that occurs in the hours and days following TBI (31, 40, 41). *Thus, could the emergence of CD16^{DIM} 14⁺ 24⁺ IGs into the circulation underlie the TBI-induced reduction in peripheral T cell numbers?* Although intriguing, proposing CD16^{DIM} 14⁺ 24⁺ IG-induced T-cell apoptosis as a mechanism of T-cell lymphopenia post-TBI is premature given that it has yet to be established whether CD16^{DIM} IGs cause T-cell death *in vivo* and the fact that no study to date has examined the surface phenotype of IGs released in response to TBI to ascertain whether this CD16^{DIM} 14⁺ 24⁺ subset is present. That said should future work address these issues and prove in the setting of TBI that such a relationship exists then a potential therapeutic target could emerge. Accelerating the maturation of immature CD16^{DIM} 14⁺ 24⁺ IGs through the systemic administration of agents capable of driving cellular differentiation could be one potential therapeutic avenue.

Exposure to Damage-Associated Molecular Patterns – A Non-Neurological Explanation for TBI-Induced Innate Immune Dysfunction

Traumatic brain injury results in the emergence into the circulation (127) and cerebrospinal fluid (128) of mitochondrial DAMPs (mtDAMPs), a heterogeneous collection of mitochondrial-derived proteins and DNA that through binding to surface-expressed and endosomal residing pattern recognition receptors exhibit immune modulatory properties. In the case of isolated TBI, mtDAMPs originate from damaged neural tissue and through promoting the priming and activation of microglia and astrocytes are likely to orchestrate in part the inflammation-induced secondary phase of brain injury (129). Diffusion across a disrupted blood–brain barrier is the most obvious mechanistic explanation for how neural-derived mtDAMPs gain entry into the circulation post-TBI (127). However, results of a recent study suggest that this may not be the only mechanism. In a seminal publication, Plog et al. have shown that inhibition of the glymphatic system, a highly organized system of CSF-interstitial fluid exchange, prevents the delivery of endogenously produced markers of brain injury into the bloodstream (130). To date, S100B, GFAP, and neuron-specific enolase have all been shown in a murine model of TBI to exit the CNS and enter the circulation through this system (130). As mtDAMPs would be released from damaged neural tissue alongside these molecules then it is not inconceivable to think that the mtDNA that has been detected in the circulation of human TBI patients (127) gained entry into the periphery via the glymphatic system.

In vitro, we have shown mtDAMPs to be potent activators of resting human neutrophils, triggering a number of robust functional responses, which include ROS generation, degranulation, and IL-8 secretion (131), while *in vivo*, injection of mtDAMPs into mice results in among other things “priming” of circulating neutrophils (132). Therefore, given their presence in the circulation of TBI patients (127), exposure to mtDAMPs may be one mechanism behind the increased basal ROS generation that has been reported in the immediate aftermath of TBI (35).

From results derived from a series of *in vivo*, *in vitro*, and *ex vivo* studies, it has recently been suggested that prior exposure to mtDAMPs, in particular N-formyl peptides, may suppress neutrophil antimicrobial function upon secondary stimulation (119). Li et al. showed *in vitro* that pretreatment with fMLP significantly reduced neutrophil chemotaxis to leukotriene B₄, while *ex vivo* studies revealed neutrophils isolated from trauma patients, in whom circulating levels of mtDAMPs are increased (132), exhibited suppressed chemotaxis to a range of chemoattractants as well as impaired neutrophil extracellular trap generation following PMA stimulation (119). Based on these observations, the phrase “DAMP-induced tolerance” was coined, which proposes that mtDAMPs may tolerize circulating neutrophils to subsequent pathogenic danger signals (119). Relating these findings to TBI, neutrophils isolated from patients with severe TBI have been shown *ex vivo* to exhibit significantly reduced ROS generation and phagocytosis when challenged with *E. coli* (36). *Thus, could it be that by initiating neutrophil activation*

in vivo, circulating mtDAMPs are responsible in part for the reduced anti-microbial activity of neutrophils post-TBI and hence the increased susceptibility of these patients to nosocomial infection? To answer this question, a greater understanding of the type and amount of mtDAMPs released following TBI and the effect that prior exposure to mtDAMPs has on other antimicrobial functions of neutrophils besides chemotaxis and NET generation is needed. Interestingly, in the field of burns research, a recent study that enrolled patients with combined inhalation and burn injury reported that elevated levels of two DAMPs, namely hyaluronic acid and double-stranded DNA, in bronchial washings were significantly associated with bacterial respiratory infection during the first 14 days after injury (133). Although neutrophil function was not investigated directly in the study, alterations in neutrophil biology were proposed as one explanation for the relationship between DAMPs and the increased susceptibility of burns' patients to infection, with the authors suggesting that DAMPs may trigger polarization of neutrophils toward an IL-10⁺ IL-12⁻ anti-inflammatory phenotype (133).

Defined as "the severely reduced capacity of a cell to respond to LPS during a second exposure to this stimulus" (134), endotoxin tolerance (ET) describes a transient refractory state, which in monocytes is characterized in part by reduced proinflammatory cytokine production and high surface expression of CD163, two features reminiscent of anti-inflammatory "M2" macrophages (135). Interestingly, mtDAMPs, in particular mtDNA, are potent inducers of ET in human monocytes (136). Fernández-Ruiz et al. (136) found that when challenged with LPS, monocytes pretreated with mtDNA exhibited among other things significantly reduced proinflammatory cytokine production and enhanced IL-10 secretion, leading to the suggestion that DAMPs may play a pivotal role in the refractory state of monocytes in "sterile" pathologies (136). On this note, significantly greater numbers of circulating anti-inflammatory "M2" monocytes and increased intracellular expression of IL-10 in monocytes has been reported post-TBI (30, 37), suggesting the presence of an immune-suppressive monocyte pool. If, as reported in other patient cohorts (136), future studies were to show that the elevation in circulating mtDNA that occurs following TBI (127) is associated with the development of monocyte ET and an increased incidence of infection, then an early assessment of the functional response of circulating monocytes to LPS may identify TBI patients at risk of developing nosocomial infection. In support of this concept, Pena et al. recently demonstrated in a cohort of critically ill patients that at the time of clinical presentation, a unique ET gene expression profile in PBMCs could be used to predict the development of sepsis and organ failure (134).

As described earlier, autoantibodies specific for CNS-residing proteins have been detected in the serum of patients that have suffered either mild (62) or severe (63) TBI. Given that damage to neural tissue results in the emergence into the circulation of mtDAMPs, *could these components lead to immune dysregulation in the TBI patient by triggering an autoimmune response?* Currently, no study to our knowledge has investigated this possibility. However, autoantibodies directed against mitochondria and mtDNA have been detected in patients with inflammatory disease (137) and neurodevelopmental disorders (138), and

anti-mtDNA antibodies have been shown *in vitro* to drive a robust proinflammatory response from circulating immune cells (137). If replicated in the setting of TBI, one could envisage how after crossing the "leaky" BBB, autoantibodies against CNS-residing mtDAMPs could trigger an inflammatory reaction from local microglia and astrocytes that contributes to the onset of secondary brain injury.

In animal models of experimental brain ischemia, the nuclear-derived DAMP high mobility group box 1 (HMGB1) has been linked to the development of CNS injury-induced immune suppression (139). Released into the extracellular environment as a consequence of cellular necrosis or active secretion by immune cells, HMGB1 was shown *in vivo* to promote the expansion of MDSCs as well as partially mediate stroke-induced lymphopenia and monocyte hyporesponsiveness (139). Given that akin to stroke, TBI results in elevated plasma levels of HMGB-1 (140), *could the presence of this DAMP in the circulation underlie not only the well-established features of TBI-induced immune suppression (e.g., lymphocytopenia and immune exhaustion) but also those immune changes we have proposed may occur following TBI (e.g., emergence of MDSCs)?* A future study that measures immune function alongside HMGB-1 levels would address this question, and if a role for HMGB-1 in TBI-induced immune suppression was found then a therapeutic target for the prevention of immune dysfunction post-TBI could emerge.

TBI AND PERIPHERAL IMMUNE SUPPRESSION – UNANSWERED QUESTIONS AND FUTURE OPPORTUNITIES

Despite the recent surge of interest in TBI and its impact on peripheral immunity (31–38, 141–143), our understanding of this subject remains equivocal at best. Thus, in this section, in an effort to move this field of research forward, a series of questions are posed, the answers to which we feel would provide much needed information not only on the mechanisms underlying TBI-induced changes in immunity but whether therapeutic intervention aimed at manipulating peripheral immune function has potential as a future treatment option for the hospitalized TBI patient.

Q1. What are the Acute and Long-Term Effects of TBI on Peripheral Immune Function?

A question that has not been properly addressed in the field of TBI and trauma research in general is *how quickly following a traumatic insult do changes in peripheral immunity occur?* In the TBI studies described in this review, collection of the first blood sample postinjury has ranged from ≤ 3 to 72 h, a broad time-frame that may explain in part some of the conflicting observations that have been reported to date in respect of the impact of TBI on peripheral immunity. Without a complete understanding of the immediate immune response to TBI, it is likely that information that may be useful for the clinician when deciding upon treatment protocols for the injured patient is being missed. For instance,

Rovlias et al. demonstrated the benefit of early blood sampling by showing that white blood cell counts in admission blood samples (within 2 h of injury) could independently predict patient outcome at 6 months (144). In another study, Pagowska-Klimek et al. measured neutrophil function in blood samples taken 0.5–2 h (mean 1 h) following isolated head injury in children and reported significantly reduced ROS generation following PMA and fMLP stimulation (145), demonstrating the immediate impact that TBI can have on peripheral immunity. However, whether this early impairment in neutrophil function resulted in an increased incidence of infection or poor outcome was not determined. Performing similar studies in adult patients that not only analyze the very early functional immune response to TBI but collect detailed information on a series of clinical outcomes, such as infection, development of sepsis, and mortality, would generate novel data that could have potential clinical benefit.

In addition to a lack of understanding of the immediate immune response to TBI, very little is known in respect of the long-term impact that TBI has on immune function. In the field of burns research, it has been reported that it takes a total of 3.5 months following thermal injury for the oxidative burst capacity of circulating neutrophils to return to a level that resembles that of healthy controls (146). In adult TBI patients, a significant reduction in the phagocytic activity of circulating neutrophils has been reported up to 2 weeks postinjury (35), while the immediate suppression in the frequency and absolute number of CD3⁺56⁺ NK cells that accompanies TBI is maintained up to 21 days postinjury (38). In rodent models of TBI, significantly reduced numbers of thymocytes, monocytes, and tissue macrophages as well as a decline in thymic mass has been recorded at 60 days postinjury (37). As these results suggest that TBI may have long-lasting detrimental effects upon the immune system, it would be interesting for future studies to assess, via a longitudinal approach, the extent to which TBI impacts upon the long-term functioning of the immune system especially since mortality as a result of infection has been reported in patients with severe TBI as late as 3 months postinjury (147).

Q2. Could a Heterogeneous Pool of Circulating Neutrophils Explain the Alterations in Neutrophil Function Observed Post-TBI?

Neutrophilia is a well-described feature of the immune response to TBI (34, 35, 39), yet no study to date has examined the composition of this enlarged neutrophil pool. Although unknown in respect to TBI, severe traumatic injury results in a heterogeneous neutrophil pool that broadly consists of two distinct subsets, namely CD16^{BRIGHT} and CD16^{DIM} (118). Compared to their CD16^{BRIGHT} counterparts, CD16^{DIM} neutrophils exhibit significantly reduced ROS generation, phagocytosis, and bacterial killing (117, 148). Given that these three neutrophil functions are significantly impaired following severe TBI (35, 36, 40, 149), *could it be that akin to other forms of traumatic injury, TBI results in a heterogeneous neutrophil pool?* Since all studies that have examined the impact of TBI on neutrophil biology to date have considered the circulating neutrophil pool to be a single

homogenous population, the answer to this question is currently unknown. By addressing this issue, a greater understanding of the mechanisms that underlie TBI-induced immune suppression would be gained and potential therapeutic targets identified.

Q3. Can Peripheral Immune Suppression and/or mtDAMPs Serve as a Biomarkers of Outcome in the Traumatically Brain Injured Patient?

Recently, a number of studies have demonstrated that changes in peripheral immunity are associated with and/or can predict outcome in TBI patients. Focusing primarily upon the inflammatory response to TBI, studies have shown increased levels of IL-6, IL-8, and IL-10 are associated with fatal outcome following severe TBI, with elevated IL-10 levels being associated with hospital mortality independent of patient age, GCS score, pupil reactivity at admission, and associated trauma (141, 142). In addition to mortality, raised serum IL-6 levels within 17 h of injury have been found to be a good prognostic marker for the development of raised intracranial pressure following isolated TBI (150), while an elevated IL-6:IL-10 ratio was associated with an increased risk of an unfavorable GOS score at 6 months postsevere TBI (143). Besides inflammatory cytokines, leukocytosis has been shown to be of prognostic significance in TBI patients. High white blood cell counts within the first day following injury have been found to be associated with a longer length of hospital stay (151), mortality (33), and unfavorable neurological outcome at 6 months, with this latter association independent of GCS score, pupillary reaction, age, and intracranial diagnosis (144, 151).

Whether the peripheral immune suppression that occurs post-TBI can be used to predict the development of infection is currently unknown, although this approach has proven to be successful in other cohorts of patients with CNS injury. In stroke patients, in whom infections are associated with higher mortality rates and poor functional outcome (152), several features of stroke-induced immune depression have been shown to be associated with and/or independently predict the development of nosocomial infection. These include: (1) reduced monocytic HLA-DR expression and low CD4⁺ T-cell counts (153, 154), (2) reduced *ex vivo* TNF- α release by monocytes (155), and (3) elevated plasma IL-10 levels (156). In addition, it has recently been postulated that a rise in the frequency of circulating CD64⁺ neutrophils 1 week after stroke may serve as a marker by which to identify an inflammatory response developing as a consequence of infection (157). In the context of TBI-induced immune suppression, no study to our knowledge has examined whether alterations in neutrophil surface phenotype can predict the development of infection, a reflection of the paucity of data in this area of research. There have however been reports of reduced ROS production by neutrophils isolated from infected TBI patients compared to non-infected patients (36). That said this relationship was not predictive and the potential impact of confounders were not considered. This lack of comprehensive statistical analysis is also a limitation of a study where infected patients with severe TBI were found to have significantly lower circulating frequencies of CD3⁺56⁺, CD3⁺4⁺ and CD3⁺8⁺ T cells as well as CD3⁺56⁺ NK cells at the time of

infection occurrence when compared to non-infected patients (31). Thus, although associated with nosocomial infection, it remains to be established whether TBI-induced immune suppression can be used to independently predict the development of infection. Given the range of adverse outcomes that are associated with infection in TBI patients (11, 14, 15, 17, 20, 21) and the benefit that early detection may have on patient health, addressing this issue should form a significant part of future TBI research.

Aside from immune function, *could the presence of mtDAMPs serve as a biomarker of injury severity or patient outcome post-TBI?* In other fields of trauma research, plasma levels of mtDNA have been found to (i) positively correlate with injury severity score (ISS) (158–160), (ii) be significantly higher in admission samples from non-survivors compared to survivors (158, 161, 162), and (iii) be predictive of and/or associated with the development of a systemic inflammatory response or multiple organ failure (160, 161). However, whether mtDAMPs are suitable diagnostic or prognostic markers in TBI is currently unclear. In the only study to our knowledge that has measured circulating mtDAMPs in human TBI patients, Wang et al. found that although significantly increased when compared to healthy controls, plasma mtDNA levels on admission did not correlate with either GCS score or ISS (127). Similarly, no association was observed between mtDNA levels in admission CSF samples and GCS score in a cohort of pediatric TBI patients (128). However, CSF mtDNA concentration was found to predict with a reasonable degree of specificity (84.2%) patient outcome at 6 months (128). More recently, in a porcine model of focal and diffuse TBI, Kilbaugh et al. reported a significant increase in relative mtDNA copy numbers in peripheral blood at 6 and 25 h postinjury (163). Interestingly, this increase was shown to correlate with a reduction in cerebral mitochondrial respiration, leading to the proposal that enumeration of relative mtDNA copy numbers in peripheral blood could represent a novel signature of cerebral mitochondrial dysfunction post-TBI (163).

Q4. Is Reversing TBI-Induced Immune Suppression a Potential Therapeutic Strategy for the Treatment of Nosocomial Infections in the Hospitalized TBI Patient?

The majority of studies that have investigated whether the immune system is a potential therapeutic target for the treatment of TBI have focused upon developing immune suppressive strategies as a means of treating and/or preventing the secondary injury phase of TBI. To date, these strategies have included (1) neutrophil depletion, which reduced edema formation and attenuated brain tissue loss (164), (2) ghrelin therapy, which reduced peripheral monocyte and neutrophil recruitment to the site of brain injury (165), and (3) blocking leukotriene synthesis, which resulted in an attenuation in brain swelling and reduced blood–brain barrier permeability (166). Given the interest in preventing secondary injury following TBI, very little is known, particularly in humans, as to whether counteracting TBI-induced immune suppression may be a useful approach for the prevention of infection in the hospitalized TBI patient. While it may seem counterintuitive to enhance immune activity to eradicate infection given that immune hyperactivity is central to the pathophysiology of secondary brain

injury, it has been suggested that such approaches would only commence when any secondary injuries are controllable (147).

In a randomized, placebo-controlled, double-blind, multicentre phase II study, Heard et al. prospectively investigated whether the use of prophylactic recombinant human granulocyte colony-stimulating factor (G-CSF) could reduce the frequency of nosocomial infections in patients with acute TBI (167). They found that while G-CSF treatment had no impact on the frequency of pneumonia or urinary tract infections, it was associated with a significant reduction in the frequency of primary bacteremias (167). However, the study found no beneficial effect for G-CSF therapy on patient mortality or length of hospital stay (167). Following on from this work, Ishikawa et al. investigated whether G-CSF treatment could reduce the incidence of life-threatening infections in eight patients with severe TBI that were undergoing combined therapy with barbiturates and mild hypothermia, a treatment protocol known to increase infection risk (147). The group found that compared to patients who did not receive G-CSF therapy, prevalence rates of pneumonia and meningitis were significantly lower in G-CSF treated patients (147). Moreover, compared to baseline values, G-CSF treatment resulted in a significant increase in circulating neutrophil numbers and antimicrobial function with respect to phagocytic and bactericidal activities, suggesting that an enhancement in immune function had protected the patients from contracting nosocomial infection (147). Given the potential clinical significance of this study, it is surprising that in the 16 years since its publication no group has taken this research forward, especially since during this time period, immunomodulation in other forms of traumatic injury has proven successful in protecting against the development of post-traumatic infection (168, 169). Thus, it remains to be established whether therapies aimed at restoring immune function would be of benefit to the hospitalized TBI patient in terms of reducing their susceptibility to infection.

CONCLUSION

In this review article, we have proposed that the emergence into the circulation of hematopoietic cells with suppressive activity underlies in part the immune suppression that is observed following TBI. If future studies prove this hypothesis to be correct then *could these cells be manipulated for the clinical benefit of the hospitalized TBI patient in respect of reducing infection risk?* Interestingly, therapeutic interventions are being trialed in other cohorts of patients to address similar questions. For instance, a series of strategies aimed at manipulating the function of MDSCs are currently under clinical investigation as a novel treatment for cancer (125), while in the field of sepsis research, groups are examining whether it is possible to remove individual neutrophil subsets from the circulation. On this note, *ex vivo* filtration of blood from patients with septic shock has been found to preferentially remove neutrophils with an activated phenotype (CD11b^{high}, CD64^{high}, and CXCR1/2^{low}) (170). If, as we have proposed, suppressive CD16^{BRIGHT} CD62L^{DIM} neutrophils emerge into the circulation following TBI and are involved in TBI-induced immune suppression then it would be of interest to determine whether a similar filtration approach to remove this specific neutrophil subset could be beneficial in terms of reducing infection risk in TBI patients.

FUNDING

JH is funded by the National Institute for Health Research Surgical Reconstruction and Microbiology Research Centre, a partnership

between University Hospitals Birmingham NHS Foundation Trust, the University of Birmingham, and the Royal Centre for Defence Medicine. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.

REFERENCES

- Menon DK, Schwab K, Wright DW, Maas AI, Demographics and Clinical Assessment Working Group of the International and Interagency Initiative toward Common Data Elements for Research on Traumatic Brain Injury and Psychological Health. Position statement: definition of traumatic brain injury. *Arch Phys Med Rehabil* (2010) **91**:1637–40. doi:10.1016/j.apmr.2010.05.017
- Health and Social Care Information Centre. *Hospital Episode Statistics, Admitted Patient Care, England 2012–13: Diagnosis* (2015). Available from: <http://www.hscic.gov.uk/catalogue/PUB16719>
- Faul M, Xu L, Wald MM, Coronado VG. *Traumatic Brain Injury in the United States: Emergency Department Visits, Hospitalizations and Deaths 2002–2006*. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control (2010).
- Schwarzbold M, Diaz A, Martins ET, Rufino A, Amante LN, Thais ME, et al. Psychiatric disorders and traumatic brain injury. *Neuropsychiatr Dis Treat* (2008) **4**:797–816.
- Whelan-Goodinson R, Ponsford J, Johnston L, Grant F. Psychiatric disorders following traumatic brain injury: their nature and frequency. *J Head Trauma Rehabil* (2009) **24**:324–32. doi:10.1097/HTR.0b013e3181a712aa
- Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, et al. Cost of disorders of the brain in Europe 2010. *Eur Neuropsychopharmacol* (2011) **21**:718–79. doi:10.1016/j.euroneuro.2011.08.008
- Langlois JA, Sattin RW. Traumatic brain injury in the United States: research and programs of the centers for disease control and prevention (CDC). *J Head Trauma Rehabil* (2005) **20**:187–8. doi:10.1097/00001199-200505000-00001
- Center TBI. *10 Facts About TBI* (2015). Available from: www.center-tbi.eu/patients/facts
- Cazzadori A, Di Perri G, Vento S, Bonora S, Fendt D, Rossi M, et al. Aetiology of pneumonia following isolated closed head injury. *Respir Med* (1997) **91**:193–9. doi:10.1016/S0954-6111(97)90038-X
- Bronchard R, Albaladejo P, Brezac G, Geffroy A, Seince PF, Morris W, et al. Early onset pneumonia: risk factors and consequences in head trauma patients. *Anesthesiology* (2004) **100**:234–9. doi:10.1097/00005542-200402000-00009
- Zygun DA, Zuege DJ, Boiteau PJ, Laupland KB, Henderson EA, Kortbeek JB, et al. Ventilator-associated pneumonia in severe traumatic brain injury. *Neurocrit Care* (2006) **5**:108–14. doi:10.1385/NCC:5:2:108
- Kourbeti IS, Papadakis JA, Neophytou C, Filippou M, Ioannou A, Karabetsos DA, et al. Infections in patients with traumatic brain injury who undergo neurosurgery. *Br J Neurosurg* (2011) **25**:9–15. doi:10.3109/02688697.2010.500411
- Kourbeti IS, Vakis AF, Papadakis JA, Karabetsos DA, Bertsias G, Filippou M, et al. Infections in traumatic brain injury patients. *Clin Microbiol Infect* (2012) **18**:359–64. doi:10.1111/j.1469-0691.2011.03625.x
- Schirmer-Mikalsen K, Moen KG, Skandsen T, Vik A, Klestad P. Intensive care and traumatic brain injury after the introduction of a treatment protocol: a prospective study. *Acta Anaesthesiol Scand* (2013) **57**:46–55. doi:10.1111/j.1399-6576.2012.02785.x
- Rincón-Ferrari MD, Flores-Cordero JM, Leal-Noval SR, Murillo-Cabezas F, Cayuelas A, Muñoz-Sánchez MA, et al. Impact of ventilator-associated pneumonia in patients with severe head injury. *J Trauma* (2004) **57**:1234–40. doi:10.1097/01.TA.0000119200.70853.23
- Rondina C, Videtta W, Petroni G, Lujan S, Schoon P, Mori LB, et al. Mortality and morbidity from moderate to severe traumatic brain injury in Argentina. *J Head Trauma Rehabil* (2005) **20**:368–76. doi:10.1097/00001199-200507000-00008
- Glance LG, Stone PW, Mukamel DB, Dick AW. Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients. *Arch Surg* (2011) **146**:794–801. doi:10.1001/archsurg.2011.41
- Selassie AW, Fakhry SM, Ford DW. Population-based study of the risk of in-hospital death after traumatic brain injury: the role of sepsis. *J Trauma* (2011) **71**:1226–34. doi:10.1097/TA.0b013e318226ecfc
- Cardozo Junior LC, Silva RR. Sepsis in intensive care unit patients with traumatic brain injury: factors associated with higher mortality. *Rev Bras Ter Intensiva* (2014) **26**:148–54. doi:10.5935/0103-507X.20140022
- Vitaz TW, Jenks J, Raque GH, Shields CB. Outcome following moderate traumatic brain injury. *Surg Neurol* (2003) **60**:285–91. doi:10.1016/S0090-3019(03)00378-1
- Piek J, Chesnut RM, Marshall LF, van Berkum-Clark M, Klauber MR, Blunt BA, et al. Extracranial complications of severe head injury. *J Neurosurg* (1992) **77**:901–7. doi:10.3171/jns.1992.77.6.0901
- Venturi L, Miranda M, Selmi V, Vitali L, Tani A, Margheri M, et al. Systemic sepsis exacerbates mild post-traumatic brain injury in the rat. *J Neurotrauma* (2009) **26**:1547–56. doi:10.1089/neu.2008-0723
- Meisel C, Schwab JM, Prass K, Meisel A, Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. *Nat Rev Neurosci* (2005) **6**:775–86. doi:10.1038/nrn1765
- Hoyt DB, Ozkan AN, Hansbrough JF, Marshall L, vanBerkum-Clark M. Head injury: an immunologic deficit in T-cell activation. *J Trauma* (1990) **30**:759–66. doi:10.1097/00005373-199007000-00001
- Quattrocchi KB, Frank EH, Miller CH, MacDermott JP, Hein L, Frey L, et al. Suppression of cellular immune activity following severe head injury. *J Neurotrauma* (1990) **7**:77–87. doi:10.1089/neu.1990.7.77
- Miller CH, Quattrocchi KB, Frank EH, Issel BW, Wagner FC Jr. Humoral and cellular immunity following severe head injury: review and current investigations. *Neurol Res* (1991) **13**:17–24.
- Quattrocchi KB, Frank EH, Miller CH, Amin A, Issel BW, Wagner FC Jr. Impairment of helper T-cell function and lymphokine-activated killer cytotoxicity following severe head injury. *J Neurosurg* (1991) **75**:766–73. doi:10.3171/jns.1991.75.5.0766
- Quattrocchi KB, Frank EH, Miller CH, Dull ST, Howard RR, Wagner FC Jr. Severe head injury: effect upon cellular immune function. *Neurol Res* (1991) **13**:13–20.
- Quattrocchi KB, Miller CH, Wagner FC Jr, DeNardo SJ, DeNardo GL, Ovodov K, et al. Cell-mediated immunity in severely head-injured patients: the role of suppressor lymphocytes and serum factors. *J Neurosurg* (1992) **77**:694–9. doi:10.3171/jns.1992.77.5.0694
- Shimonkevitz R, Bar-Or D, Harris L, Dole K, McLaughlin L, Yudel R. Transient monocyte release of interleukin-10 in response to traumatic brain injury. *Shock* (1999) **12**:10–6. doi:10.1097/00024382-199907000-00002
- Mrakovcic-Sutic I, Tokmadzic VS, Laskarin G, Mahmutefendic H, Lucin P, Zupan Z, et al. Early changes in frequency of peripheral blood lymphocyte subpopulations in severe traumatic brain-injured patients. *Scand J Immunol* (2010) **72**:57–65. doi:10.1111/j.1365-3083.2010.02407.x
- Sotosek Tokmadzic V, Laskarin G, Mahmutefendic H, Lucin P, Mrakovcic-Sutic I, Zupan Z, et al. Expression of cytolytic protein-perforin in peripheral blood lymphocytes in severe traumatic brain injured patients. *Injury* (2012) **43**:624–31. doi:10.1016/j.injury.2010.05.009
- Subramanian A, Agrawal D, Pandey RM, Nimiya M, Albert V. The leukocyte count, immature granulocyte count and immediate outcome in head injury patients. In: Agrawal A, editor. *Brain Injury – Pathogenesis, Monitoring, Recovery and Management* (2012). doi:10.5772/27020
- Junger WG, Rhind SG, Rizoli SB, Cuschieri J, Baker AJ, Shek PN, et al. Prehospital hypertonic saline resuscitation attenuates the activation and promotes apoptosis of neutrophils in patients with severe traumatic brain injury. *Shock* (2013) **40**:366–74. doi:10.1097/SHK.0000000000000038
- Liao Y, Liu P, Guo F, Zhang ZY, Zhang Z. Oxidative burst of circulating neutrophils following traumatic brain injury in human. *PLoS One* (2013) **8**:e68963. doi:10.1371/journal.pone.0068963

36. Marks W, Golabek-Dropiewska K, Bryl E, Dudek R, Wieruszewski J, Stasiak M, et al. Immunomonitoring in patients with early moderate and severe head trauma. *Cent Eur J Public Health* (2013) **38**:494–9. doi:10.5114/ceji.2013.39767
37. Schwulst SJ, Trahanas DM, Saber R, Perlman H. Traumatic brain injury-induced alterations in peripheral immunity. *J Trauma Acute Care Surg* (2013) **75**:780–8. doi:10.1097/TA.0b013e318299616a
38. Kong XD, Bai S, Chen X, Wei HJ, Jin WN, Li MS, et al. Alterations of natural killer cells in traumatic brain injury. *Neurosci Bull* (2014) **30**:903–12. doi:10.1007/s12264-014-1481-9
39. Rhind SG, Crnko NT, Baker AJ, Morrison LJ, Shek PN, Scarpelini S, et al. Prehospital resuscitation with hypertonic saline-dextran modulates inflammatory, coagulation and endothelial activation marker profiles in severe traumatic brain injured patients. *J Neuroinflammation* (2010) **7**:5. doi:10.1186/1742-2094-7-5
40. Wolach B, Szabon L, Gavriel R, Broda A, Schlesinger M. Early immunological defects in comatose patients after acute brain injury. *J Neurosurg* (2001) **94**:706–11. doi:10.3171/jns.2001.94.5.0706
41. Smrcka M, Mrlián A, Klabusay M. Immune system status in the patients after severe brain injury. *Bratisl Lek Listy* (2005) **106**:144–6.
42. Liles WC, Dale DC, Klebanoff SJ. Glucocorticoids inhibit apoptosis of human neutrophils. *Blood* (1995) **86**:3181–8.
43. Yu L, Quinn MT, Cross AR, Dinauer MC. Gp91(phox) is the heme binding subunit of the superoxide-generating NADPH oxidase. *Proc Natl Acad Sci U S A* (1998) **95**:7993–8. doi:10.1073/pnas.95.14.7993
44. Conway Morris A, Kefala K, Wilkinson TS, Dhaliwal K, Farrell L, Walsh T, et al. C5a mediates peripheral blood neutrophil dysfunction in critically ill patients. *Am J Respir Crit Care Med* (2009) **180**:19–28. doi:10.1164/rccm.200812-1928OC
45. Morris AC, Brittan M, Wilkinson TS, McAuley DF, Antonelli J, McCulloch C, et al. C5a-mediated neutrophil dysfunction is RhoA-dependent and predicts infection in critically ill patients. *Blood* (2011) **117**:5178–88. doi:10.1182/blood-2010-08-304667
46. Caron E, Hall A. Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases. *Science* (1998) **282**:1717–21. doi:10.1126/science.282.5394.1717
47. Leinase I, Rozanski M, Harhausen D, Thurman JM, Schmidt OI, Hossini AM, et al. Inhibition of the alternative complement activation pathway in traumatic brain injury by a monoclonal anti-factor B antibody: a randomized placebo-controlled study in mice. *J Neuroinflammation* (2007) **4**:13. doi:10.1186/1742-2094-4-13
48. Neher MD, Weckbach S, Flierl MA, Huber-Lang MS, Stahel PF. Molecular mechanisms of inflammation and tissue injury after major trauma – is complement the “bad guy”? *J Biomed Sci* (2011) **18**:90. doi:10.1186/1423-0127-18-90
49. Sewell DL, Nacewicz B, Liu F, Macvilay S, Erdei A, Lambris JD, et al. Complement C3 and C5 play critical roles in traumatic brain cryoinjury: blocking effects on neutrophil extravasation by C5a receptor antagonist. *J Neuroimmunol* (2004) **155**:55–63. doi:10.1016/j.jneuroim.2004.06.003
50. Wong KL, Yeap WH, Tai JJ, Ong SM, Dang TM, Wong SC. The three human monocyte subsets: implications for health and disease. *Immunol Res* (2012) **53**:41–57. doi:10.1007/s12026-012-8297-3
51. Ziegler-Heitbrock L. The CD14+ CD16+ blood monocytes: their role in infection and inflammation. *J Leukoc Biol* (2007) **81**:584–92. doi:10.1189/jlb.0806510
52. Harpals AC, Martin GE, Angelovich TA, Cheng WJ, Maisa A, Landay AL, et al. Aging is associated with chronic innate immune activation and dysregulation of monocyte phenotype and function. *Aging Cell* (2012) **11**:867–75. doi:10.1111/j.1474-9726.2012.00851.x
53. Yang J, Zhang L, Yu C, Yang XF, Wang H. Monocyte and macrophage differentiation: circulation inflammatory monocyte as biomarker for inflammatory diseases. *Biomark Res* (2014) **2**:1. doi:10.1186/2050-7771-2-1
54. Lunemann A, Lünemann JD, Roberts S, Messmer B, Barreira da Silva R, Raine CS, et al. Human NK cells kill resting but not activated microglia via NKG2D- and NKp46-mediated recognition. *J Immunol* (2008) **181**:6170–7. doi:10.4049/jimmunol.181.9.6170
55. Aloisi F. Immune function of microglia. *Glia* (2001) **36**:165–79. doi:10.1002/glia.1106
56. Hao J, Liu R, Piao W, Zhou Q, Vollmer TL, Campagnolo DI, et al. Central nervous system (CNS)-resident natural killer cells suppress Th17 responses and CNS autoimmune pathology. *J Exp Med* (2010) **207**:1907–21. doi:10.1084/jem.20092749
57. Hao J, Campagnolo D, Liu R, Piao W, Shi S, Hu B, et al. Interleukin-2/interleukin-2 antibody therapy induces target organ natural killer cells that inhibit central nervous system inflammation. *Ann Neurol* (2011) **69**:721–34. doi:10.1002/ana.22339
58. Armant M, Delespesse G, Sarfati M. IL-2 and IL-7 but not IL-12 protect natural killer cells from death by apoptosis and up-regulate bcl-2 expression. *Immunology* (1995) **85**:331–7.
59. Arruvito L, Giulianelli S, Flores AC, Paladino N, Barboza M, Lanari C, et al. NK cells expressing a progesterone receptor are susceptible to progesterone-induced apoptosis. *J Immunol* (2008) **180**:5746–53. doi:10.4049/jimmunol.180.8.5746
60. Smyth MJ, Ortaldo JR, Bere W, Yagita H, Okumura K, Young HA. IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. *J Immunol* (1990) **145**:1159–66.
61. Meert KL, Long M, Kaplan J, Sarnaik AP. Alterations in immune function following head injury in children. *Crit Care Med* (1995) **23**:822–8. doi:10.1097/00003246-199505000-00008
62. Marchi N, Bazarian JJ, Puvanna V, Janigro M, Ghosh C, Zhong J, et al. Consequences of repeated blood-barrier disruption in football players. *PLoS One* (2013) **8**:e56805. doi:10.1371/journal.pone.0056805
63. Zhang Z, Zoltewicz JS, Mondello S, Newsom KJ, Yang Z, Yang B, et al. Human traumatic brain injury induces autoantibody response against glial fibrillary acidic protein and its breakdown products. *PLoS One* (2014) **9**:e92698. doi:10.1371/journal.pone.0092698
64. Nakai A, Hayano Y, Furuta F, Noda M, Suzuki K. Control of lymphocyte egress from lymph nodes through beta2-adrenergic receptors. *J Exp Med* (2014) **211**:2583–98. doi:10.1084/jem.20141132
65. Clifton GL, Ziegler MG, Grossman RG. Circulating catecholamines and sympathetic activity after head injury. *Neurosurgery* (1981) **8**:10–4. doi:10.1097/00006123-198101000-00003
66. Hamill RW, Woolf PD, McDonald JV, Lee LA, Kelly M. Catecholamines predict outcome in traumatic brain injury. *Ann Neurol* (1987) **21**:438–43. doi:10.1002/ana.410210504
67. Katsuura G, Arimura A, Koves K, Gottschall PE. Involvement of organum vasculosum of lamina terminalis and preoptic area in interleukin 1 beta-induced ACTH release. *Am J Physiol* (1990) **258**:E163–71.
68. Dantzer R, Konsman JP, Bluthé RM, Kelley KW. Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent? *Auton Neurosci* (2000) **85**:60–5. doi:10.1016/S1566-0702(00)00220-4
69. Aspelund A, Antila S, Proulx ST, Karlén TV, Karaman S, Detmar M, et al. A dural lymphatic vascular system that drains brain interstitial fluid and macromolecules. *J Exp Med* (2015) **212**:991–9. doi:10.1084/jem.20142290
70. Louveau A. Structural and functional features of central nervous system lymphatic vessels. *Nature* (2015) **523**:337–41. doi:10.1038/nature14432
71. Cserr HF, Harling-Berg CJ, Knopf PM. Drainage of brain extracellular fluid into blood and deep cervical lymph and its immunological significance. *Brain Pathol* (1992) **2**:269–76. doi:10.1111/j.1750-3639.1992.tb00703.x
72. Webster JL, Tonelli L, Sternberg EM. Neuroendocrine regulation of immunity. *Annu Rev Immunol* (2002) **20**:125–63. doi:10.1146/annurev.immunol.20.082401.104914
73. Lee SW, Tsou AP, Chan H, Thomas J, Petrie K, Eugui EM, et al. Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA. *Proc Natl Acad Sci U S A* (1988) **85**:1204–8. doi:10.1073/pnas.85.4.1204
74. Szabó C, Thiemermann C, Wu CC, Perretti M, Vane JR. Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. *Proc Natl Acad Sci U S A* (1994) **91**:271–5. doi:10.1073/pnas.91.1.271
75. Hodge S, Hodge G, Flower R, Han P. Methyl-prednisolone up-regulates monocyte interleukin-10 production in stimulated whole blood. *Scand J Immunol* (1999) **49**:548–53. doi:10.1046/j.1365-3083.1999.00538.x
76. Steer JH, Kroeger KM, Abraham LJ, Joyce DA. Glucocorticoids suppress tumor necrosis factor-alpha expression by human monocytic THP-1 cells by suppressing transactivation through adjacent NF-kappa B and c-Jun-activating transcription factor-2 binding sites in the promoter. *J Biol Chem* (2000) **275**:18432–40. doi:10.1074/jbc.M906304199

77. Ray KP, Farrow S, Daly M, Talabot F, Searle N. Induction of the E-selectin promoter by interleukin 1 and tumour necrosis factor alpha, and inhibition by glucocorticoids. *Biochem J* (1997) **328**(Pt 2):707–15. doi:10.1042/bj3280707
78. Ramírez F, Fowell DJ, Puklavec M, Simmonds S, Mason D. Glucocorticoids promote a TH2 cytokine response by CD4+ T cells in vitro. *J Immunol* (1996) **156**:2406–12.
79. Franchimont D, Galon J, Gadina M, Visconti R, Zhou Y, Aringer M, et al. Inhibition of Th1 immune response by glucocorticoids: dexamethasone selectively inhibits IL-12-induced Stat4 phosphorylation in T lymphocytes. *J Immunol* (2000) **164**:1768–74. doi:10.4049/jimmunol.164.4.1768
80. Kraaij MD, van der Kooij SW, Reinders ME, Koekkoek K, Rabelink TJ, van Kooten C, et al. Dexamethasone increases ROS production and T cell suppressive capacity by anti-inflammatory macrophages. *Mol Immunol* (2011) **49**:549–57. doi:10.1016/j.molimm.2011.10.002
81. Duggal NA, Upton J, Phillips AC, Hampson P, Lord JM. NK cell immunosenescence is increased by psychological but not physical stress in older adults associated with raised cortisol and reduced perforin expression. *Age (Dordr)* (2015) **37**:9748. doi:10.1007/s11357-015-9748-2
82. Jones CJ, Morris KJ, Jayson MI. Prednisolone inhibits phagocytosis by polymorphonuclear leucocytes via steroid receptor mediated events. *Ann Rheum Dis* (1983) **42**:56–62. doi:10.1136/ard.42.1.56
83. Tuckermann JP, Kleiman A, McPherson KG, Reichardt HM. Molecular mechanisms of glucocorticoids in the control of inflammation and lymphocyte apoptosis. *Crit Rev Clin Lab Sci* (2005) **42**:71–104. doi:10.1080/1040836059088983
84. Schwiebert LM, Schleimer RP, Radka SF, Ono SJ. Modulation of MHC class II expression in human cells by dexamethasone. *Cell Immunol* (1995) **165**:12–9. doi:10.1006/cimm.1995.1181
85. Pan J, Ju D, Wang Q, Zhang M, Xia D, Zhang L, et al. Dexamethasone inhibits the antigen presentation of dendritic cells in MHC class II pathway. *Immunol Lett* (2001) **76**:153–61. doi:10.1016/S0165-2478(01)00183-3
86. Bellinger DL, Lorton D. Autonomic regulation of cellular immune function. *Auton Neurosci* (2014) **182**:15–41. doi:10.1016/j.autneu.2014.01.006
87. Takamoto T, Hori Y, Koga Y, Toshima H, Hara A, Yokoyama MM. Norepinephrine inhibits human natural killer cell activity in vitro. *Int J Neurosci* (1991) **58**:127–31. doi:10.3109/00207459108987189
88. van der Poll T, Coyle SM, Barbosa K, Braxton CC, Lowry SF. Epinephrine inhibits tumor necrosis factor-alpha and potentiates interleukin 10 production during human endotoxemia. *J Clin Invest* (1996) **97**:713–9. doi:10.1172/JCI118469
89. Elenkov IJ, Papanicolaou DA, Wilder RL, Chrousos GP. Modulatory effects of glucocorticoids and catecholamines on human interleukin-12 and interleukin-10 production: clinical implications. *Proc Assoc Am Physicians* (1996) **108**:374–81.
90. Trabold B, Lunz D, Gruber M, Froehlich D, Graf B. Restoration of neutrophil immunocompetence after cardiopulmonary bypass by beta-adrenergic blockers. *Surgery* (2010) **147**:562–74. doi:10.1016/j.surg.2009.10.028
91. Du Q, Min S, Chen LY, Ma YD, Guo XL, Wang Z, et al. Major stress hormones suppress the response of macrophages through down-regulation of TLR2 and TLR4. *J Surg Res* (2012) **173**:354–61. doi:10.1016/j.jss.2010.10.016
92. Panina-Bordignon P, Mazzeo D, Lucia PD, D'Ambrosio D, Lang R, Fabbri L, et al. Beta2-agonists prevent Th1 development by selective inhibition of interleukin 12. *J Clin Invest* (1997) **100**:1513–9. doi:10.1172/JCI119674
93. Woiciechowsky C, Asadullah K, Nestler D, Eberhardt B, Platzter C, Schöning B, et al. Sympathetic activation triggers systemic interleukin-10 release in immunodepression induced by brain injury. *Nat Med* (1998) **4**:808–13. doi:10.1038/nm0798-808
94. Woiciechowsky C, Schöning B, Daberkow N, Asche K, Stoltenburg G, Lanksch WR, et al. Brain-IL-1beta induces local inflammation but systemic anti-inflammatory response through stimulation of both hypothalamic-pituitary-adrenal axis and sympathetic nervous system. *Brain Res* (1999) **816**:563–71. doi:10.1016/S0006-8993(98)01238-4
95. Prass K, Meisel C, Höflich C, Braun J, Halle E, Wolf T, et al. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. *J Exp Med* (2003) **198**:725–36. doi:10.1084/jem.20021098
96. Arbabi S, Campion EM, Hemmila MR, Barker M, Dimo M, Ahrns KS, et al. Beta-blocker use is associated with improved outcomes in adult trauma patients. *J Trauma* (2007) **62**:56–61. doi:10.1097/TA.0b013e31802d972b
97. Cotton BA, Snodgrass KB, Fleming SB, Carpenter RO, Kemp CD, Arbogast PG, et al. Beta-blocker exposure is associated with improved survival after severe traumatic brain injury. *J Trauma* (2007) **62**:26–33. doi:10.1097/TA.0b013e31802d02d0
98. Inaba K, Teixeira PG, David JS, Chan LS, Salim A, Brown C, et al. Beta-blockers in isolated blunt head injury. *J Am Coll Surg* (2008) **206**:432–8. doi:10.1016/j.jamcollsurg.2007.10.005
99. MacKenzie ET, McCulloch J, Harper AM. Influence of endogenous norepinephrine on cerebral blood flow and metabolism. *Am J Physiol* (1976) **231**:489–94.
100. Meyer JS, Miyakawa Y, Welch KM, Itoh Y, Ishihara N, Chabi E, et al. Influence of adrenergic receptor blockade on circulatory and metabolic effects of disordered neurotransmitter function in stroke patients. *Stroke* (1976) **7**:158–67. doi:10.1161/01.STR.7.2.158
101. Neil-Dwyer G, Walter P, Cruickshank JM, Doshi B, O'Gorman P. Effect of propranolol and phentolamine on myocardial necrosis after subarachnoid haemorrhage. *Br Med J* (1978) **2**:990–2. doi:10.1136/bmj.2.6143.990
102. Schroepel TJ, Fischer PE, Zarza BL, Magnotti LJ, Clement LP, Fabian TC, et al. Beta-adrenergic blockade and traumatic brain injury: protective? *J Trauma* (2010) **69**:776–82. doi:10.1097/TA.0b013e3181e981b8
103. Borovikova LV, Ivanova S, Zhang M, Yang H, Botchkina GI, Watkins LR, et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. *Nature* (2000) **405**:458–62. doi:10.1038/35013070
104. Tracey KJ. The inflammatory reflex. *Nature* (2002) **420**:853–9. doi:10.1038/nature01321
105. van Westerloo DJ, Giebelen IA, Florquin S, Daalhuisen J, Bruno MJ, de Vos AF, et al. The cholinergic anti-inflammatory pathway regulates the host response during septic peritonitis. *J Infect Dis* (2005) **191**:2138–48. doi:10.1086/430323
106. Parrish WR, Rosas-Ballina M, Gallowitsch-Puerta M, Ochani M, Ochani K, Yang LH, et al. Modulation of TNF release by choline requires alpha7 subunit nicotinic acetylcholine receptor-mediated signaling. *Mol Med* (2008) **14**:567–74. doi:10.2119/2008-00079.Parrish
107. Guarini S, Altavilla D, Cainazzo MM, Giuliani D, Bigiani A, Marini H, et al. Efferent vagal fibre stimulation blunts nuclear factor-kappaB activation and protects against hypovolemic hemorrhagic shock. *Circulation* (2003) **107**:1189–94. doi:10.1161/01.CIR.0000050627.90734.ED
108. Bernik TR, Friedman SG, Ochani M, DiRaimo R, Susarla S, Czura CJ, et al. Cholinergic antiinflammatory pathway inhibition of tumor necrosis factor during ischemia reperfusion. *J Vasc Surg* (2002) **36**:1231–6. doi:10.1067/mva.2002.129643
109. Borovikova LV, Ivanova S, Nardi D, Zhang M, Yang H, Ombrellino M, et al. Role of vagus nerve signaling in CNI-1493-mediated suppression of acute inflammation. *Auton Neurosci* (2000) **85**:141–7. doi:10.1016/S1566-0702(00)00233-2
110. Saeed RW, Varma S, Peng-Nemeroff T, Sherry B, Balakhaneh D, Huston J, et al. Cholinergic stimulation blocks endothelial cell activation and leukocyte recruitment during inflammation. *J Exp Med* (2005) **201**:1113–23. doi:10.1084/jem.20040463
111. Wang H, Yu M, Ochani M, Amella CA, Tanovic M, Susarla S, et al. Nicotinic acetylcholine receptor alpha7 subunit is an essential regulator of inflammation. *Nature* (2003) **421**:384–8. doi:10.1038/nature01339
112. Kawahara E, Ikeda S, Miyahara Y, Kohno S. Role of autonomic nervous dysfunction in electrocardio-graphic abnormalities and cardiac injury in patients with acute subarachnoid hemorrhage. *Circ J* (2003) **67**:753–6. doi:10.1253/circj.67.753
113. Kox M, Pompe JC, Pickkers P, Hoedemaekers CW, van Vugt AB, van der Hoeven JG. Increased vagal tone accounts for the observed immune paralysis in patients with traumatic brain injury. *Neurology* (2008) **70**:480–5. doi:10.1212/01.wnl.0000279479.69502.3e
114. Hall S, Kumaria A, Belli A. The role of vagus nerve overactivity in the increased incidence of pneumonia following traumatic brain injury. *Br J Neurosurg* (2014) **28**:181–6. doi:10.3109/02688697.2013.835373
115. Ochoa JB, Bernard AC, O'Brien WE, Griffen MM, Maley ME, Rockich AK, et al. Arginase I expression and activity in human mononuclear cells after injury. *Ann Surg* (2001) **233**:393–9. doi:10.1097/00000658-200103000-00014

116. Bryk JA, Popovic PJ, Zenati MS, Munera V, Pribis JP, Ochoa JB. Nature of myeloid cells expressing arginase 1 in peripheral blood after trauma. *J Trauma* (2010) **68**:843–52. doi:10.1097/TA.0b013e3181b026e4
117. Pillay J, Ramakers BP, Kamp VM, Loi AL, Lam SW, Hietbrink F, et al. Functional heterogeneity and differential priming of circulating neutrophils in human experimental endotoxemia. *J Leukoc Biol* (2010) **88**:211–20. doi:10.1189/jlb.1209793
118. Pillay J, Kamp VM, van Hoven E, Visser T, Tak T, Lammers JW, et al. A subset of neutrophils in human systemic inflammation inhibits T cell responses through Mac-1. *J Clin Invest* (2012) **122**:327–36. doi:10.1172/JCI57990
119. Li H, Itagaki K, Sandler N, Gallo D, Galenkamp A, Kaczmarek E, et al. Mitochondrial damage-associated molecular patterns from fractures suppress pulmonary immune responses via formyl peptide receptors 1 and 2. *J Trauma Acute Care Surg* (2015) **78**:272–9. doi:10.1097/TA.0000000000000509
120. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. *Nat Rev Immunol* (2009) **9**:162–74. doi:10.1038/nri2506
121. Filipazzi P, Huber V, Rivoltini L. Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients. *Cancer Immunol Immunother* (2012) **61**:255–63. doi:10.1007/s00262-011-1161-9
122. Zhang K, Bai X, Li R, Xiao Z, Chen J, Yang F, et al. Endogenous glucocorticoids promote the expansion of myeloid-derived suppressor cells in a murine model of trauma. *Int J Mol Med* (2012) **30**:277–82. doi:10.3892/ijmm.2012.1014
123. Jin J, Wang X, Wang Q, Guo X, Cao J, Zhang X, et al. Chronic psychological stress induces the accumulation of myeloid-derived suppressor cells in mice. *PLoS One* (2013) **8**:e74497. doi:10.1371/journal.pone.0074497
124. Janols H, Bergenfelz C, Allaoui R, Larsson AM, Rydén L, Björnsson S, et al. A high frequency of MDSCs in sepsis patients, with the granulocytic subtype dominating in gram-positive cases. *J Leukoc Biol* (2014) **96**:685–93. doi:10.1189/jlb.5H10214-074R
125. Wesolowski R, Markowitz J, Carson WE III. Myeloid derived suppressor cells – a new therapeutic target in the treatment of cancer. *J Immunother Cancer* (2013) **1**:10. doi:10.1186/2051-1426-1-10
126. Guérin E, Orabona M, Raquil MA, Giraudeau B, Bellier R, Gibot S, et al. Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration*. *Crit Care Med* (2014) **42**:2007–18. doi:10.1097/CCM.0000000000000344
127. Wang HC, Lin YJ, Tsai NW, Su BY, Kung CT, Chen WF, et al. Serial plasma deoxyribonucleic acid levels as predictors of outcome in acute traumatic brain injury. *J Neurotrauma* (2014) **31**:1039–45. doi:10.1089/neu.2013.3070
128. Walko TD III, Bola RA, Hong JD, Au AK, Bell MJ, Kochanek PM, et al. Cerebrospinal fluid mitochondrial DNA: a novel DAMP in pediatric traumatic brain injury. *Shock* (2014) **41**:499–503. doi:10.1097/SHK.0000000000000160
129. Gyoneva S, Ransohoff RM. Inflammatory reaction after traumatic brain injury: therapeutic potential of targeting cell-cell communication by chemokines. *Trends Pharmacol Sci* (2015) **36**:471–80. doi:10.1016/j.tips.2015.04.003
130. Plog BA, Dashnaw ML, Hitomi E, Peng W, Liao Y, Lou N, et al. Biomarkers of traumatic injury are transported from brain to blood via the glymphatic system. *J Neurosci* (2015) **35**:518–26. doi:10.1523/JNEUROSCI.3742-14.2015
131. Hazardine J, Hampson P, Opoku FA, Foster M, Lord JM. N-Formyl peptides drive mitochondrial damage associated molecular pattern induced neutrophil activation through ERK1/2 and P38 MAP kinase signalling pathways. *Injury* (2015) **46**(6):975–84. doi:10.1016/j.injury.2015.03.028
132. Zhang Q, Raoof M, Chen Y, Sumi Y, Sursal T, Junger W, et al. Circulating mitochondrial DAMPs cause inflammatory responses to injury. *Nature* (2010) **464**:104–7. doi:10.1038/nature08780
133. Maile R, Jones S, Pan Y, Zhou H, Jaspers I, Peden DB, et al. Association between early airway damage-associated molecular patterns and subsequent bacterial infection in patients with inhalation and burn injury. *Am J Physiol Lung Cell Mol Physiol* (2015) **308**(9):L855–60. doi:10.1152/ajplung.00321.2014
134. Pena OM, Hancock DG, Lyle NH, Linder A, Russell JA, Xia J, et al. An endotoxin tolerance signature predicts sepsis and organ dysfunction at initial clinical presentation. *EBioMedicine* (2014) **1**:64–71. doi:10.1016/j.ebiom.2014.10.003
135. Martinez FO, Gordon S. The M1 and M2 paradigm of macrophage activation: time for reassessment. *F1000Prime Rep* (2014) **6**:13. doi:10.12703/P6-13
136. Fernández-Ruiz I, Arnalich F, Cubillos-Zapata C, Hernández-Jiménez E, Moreno-González R, Toledano V, et al. Mitochondrial DAMPs induce endotoxin tolerance in human monocytes: an observation in patients with myocardial infarction. *PLoS One* (2014) **9**:e95073. doi:10.1371/journal.pone.0095073
137. Wang H, Li T, Chen S, Gu Y, Ye S. NETs mitochondrial DNA and its auto-antibody in systemic lupus erythematosus and a proof-of-concept trial of metformin. *Arthritis Rheumatol* (2015). doi:10.1002/art.39296
138. Zhang B, Angelidou A, Alysandratos KD, Vasiadi M, Francis K, Asadi S, et al. Mitochondrial DNA and anti-mitochondrial antibodies in serum of autistic children. *J Neuroinflammation* (2010) **7**:80. doi:10.1186/1742-2094-7-80
139. Liesz A, Dalpke A, Mracsko E, Antoine DJ, Roth S, Zhou W, et al. DAMP signaling is a key pathway inducing immune modulation after brain injury. *J Neurosci* (2015) **35**:583–98. doi:10.1523/JNEUROSCI.2439-14.2015
140. Wang KY, Yu GF, Zhang ZY, Huang Q, Dong XQ. Plasma high-mobility group box 1 levels and prediction of outcome in patients with traumatic brain injury. *Clin Chim Acta* (2012) **413**:1737–41. doi:10.1016/j.cca.2012.07.002
141. Schneider Soares FM, Menezes de Souza N, Libório Schwarzbold M, Paim Diaz A, Costa Nunes J, Hohl A, et al. Interleukin-10 is an independent biomarker of severe traumatic brain injury prognosis. *Neuroimmunomodulation* (2012) **19**:377–85. doi:10.1159/000342141
142. Ferreira LC, Regner A, Miotto KD, Moura Sd, Ikuta N, Vargas AE, et al. Increased levels of interleukin-6, -8 and -10 are associated with fatal outcome following severe traumatic brain injury. *Brain Inj* (2014) **28**:1311–6. doi:10.3109/02699052.2014.916818
143. Kumar RG, Boles JA, Wagner AK. Chronic inflammation after severe traumatic brain injury: characterization and associations with outcome at 6 and 12 months postinjury. *J Head Trauma Rehabil* (2014). doi:10.1097/HTR.0000000000000067
144. Rovlias A, Kotsou S. The blood leukocyte count and its prognostic significance in severe head injury. *Surg Neurol* (2001) **55**:190–6. doi:10.1016/S0090-3019(01)00414-1
145. Pagowska-Klimek I, Lewkowicz P, Banasik M, Krajewski W, Tchórzewski H. Isolated head injury in children affects the neutrophil function and lymphocyte count. *J Trauma* (2007) **63**:179–86. doi:10.1097/TA.0b013e3180340dc9
146. Parment K, Zetterberg A, Ernerudh J, Bakteman K, Steinwall J, Sjoberg F. Long-term immunosuppression in burned patients assessed by in vitro neutrophil oxidative burst (Phagoburst). *Burns* (2007) **33**:865–71. doi:10.1016/j.burns.2006.11.011
147. Ishikawa K, Tanaka H, Takaoka M, Ogura H, Shiozaki T, Hosotsubo H, et al. Granulocyte colony-stimulating factor ameliorates life-threatening infections after combined therapy with barbiturates and mild hypothermia in patients with severe head injuries. *J Trauma* (1999) **46**:999–1007. doi:10.1097/00005373-199906000-00004
148. Drifte G, Dunn-Siegrist I, Tissières P, Pugin J. Innate immune functions of immature neutrophils in patients with sepsis and severe systemic inflammatory response syndrome. *Crit Care Med* (2013) **41**:820–32. doi:10.1097/CCM.0b013e318274647d
149. Wolach B, Szabon L, Gavrieli R, Ben-Tovim T, Zagreba F, Schlesinger M. Some aspects of the humoral and neutrophil functions in post-comatose awareness patients. *Brain Inj* (1993) **7**:401–10. doi:10.3109/02699059309029683
150. Hergenroeder GW, Moore AN, McCoy JP Jr, Samsel L, Ward NH III, Clifton GL, et al. Serum IL-6: a candidate biomarker for intracranial pressure elevation following isolated traumatic brain injury. *J Neuroinflammation* (2010) **7**:19. doi:10.1186/1742-2094-7-19
151. Gürkanlar D, Lakadamyali H, Ergun T, Yilmaz C, Yücel E, Altınörs N. Predictive value of leucocytosis in head trauma. *Türk Neurosurg* (2009) **19**:211–5.
152. Vermeij FH, Scholte op Reimer WJ, de Man P, van Oostenbrugge RJ, Franke CL, de Jong G, et al. Stroke-associated infection is an independent risk factor for poor outcome after acute ischemic stroke: data from the Netherlands stroke survey. *Cerebrovasc Dis* (2009) **27**:465–71. doi:10.1159/000210094
153. Harms H, Prass K, Meisel C, Klehmet J, Rogge W, Drenckhahn C, et al. Preventive antibacterial therapy in acute ischemic stroke: a randomized controlled trial. *PLoS One* (2008) **3**:e2158. doi:10.1371/journal.pone.0002158
154. Vogelgesang A, Grunwald U, Langner S, Jack R, Bröker BM, Kessler C, et al. Analysis of lymphocyte subsets in patients with stroke and their influence on infection after stroke. *Stroke* (2008) **39**:237–41. doi:10.1161/STROKEAHA.107.493635
155. Urra X, Cervera A, Obach V, Climent N, Planas AM, Chamorro A. Monocytes are major players in the prognosis and risk of infection after acute stroke. *Stroke* (2009) **40**:1262–8. doi:10.1161/STROKEAHA.108.532085

156. Klehmet J, Harms H, Richter M, Prass K, Volk HD, Dirnagl U, et al. Stroke-induced immunodepression and post-stroke infections: lessons from the preventive antibacterial therapy in stroke trial. *Neuroscience* (2009) **158**:1184–93. doi:10.1016/j.neuroscience.2008.07.044
157. Polyovich A, Biró E, Orbán C, Bajnok A, Varga V, Béres-Molnár AK, et al. Relevance of novel inflammatory markers in stroke-induced immunosuppression. *BMC Neurol* (2014) **14**:41. doi:10.1186/1471-2377-14-41
158. Lam NY, Rainer TH, Chiu RW, Joynt GM, Lo YM. Plasma mitochondrial DNA concentrations after trauma. *Clin Chem* (2004) **50**:213–6. doi:10.1373/clinchem.2003.025783
159. Yamanouchi S, Kudo D, Yamada M, Miyagawa N, Furukawa H, Kushimoto S. Plasma mitochondrial DNA levels in patients with trauma and severe sepsis: time course and the association with clinical status. *J Crit Care* (2013) **28**:1027–31. doi:10.1016/j.jcrc.2013.05.006
160. Gu X, Yao Y, Wu G, Lv T, Luo L, Song Y. The plasma mitochondrial DNA is an independent predictor for post-traumatic systemic inflammatory response syndrome. *PLoS One* (2013) **8**:e72834. doi:10.1371/journal.pone.0072834
161. Simmons JD, Lee YL, Mulekar S, Kuck JL, Brevard SB, Gonzalez RP, et al. Elevated levels of plasma mitochondrial DNA DAMPs are linked to clinical outcome in severely injured human subjects. *Ann Surg* (2013) **258**:591–8. doi:10.1097/SLA.0b013e3182a4ea46
162. Krychtiuk KA, Ruhittel S, Hohensinner PJ, Koller L, Kaun C, Lenz M, et al. Mitochondrial DNA and toll-like receptor-9 are associated with mortality in critically ill patients. *Crit Care Med* (2015). doi:10.1097/CCM.0000000000001311
163. Kilbaugh TJ, Lvova M, Karlsson M, Zhang Z, Leipzig J, Wallace DC, et al. Peripheral blood mitochondrial DNA as a biomarker of cerebral mitochondrial dysfunction following traumatic brain injury in a porcine model. *PLoS One* (2015) **10**:e0130927. doi:10.1371/journal.pone.0130927
164. Kenne E, Erlandsson A, Lindbom L, Hillered L, Clausen F. Neutrophil depletion reduces edema formation and tissue loss following traumatic brain injury in mice. *J Neuroinflammation* (2012) **9**:17. doi:10.1186/1742-2094-9-17
165. Lee J, Costantini TW, D'Mello R, Eliceiri BP, Coimbra R, Bansal V. Altering leukocyte recruitment following traumatic brain injury with ghrelin therapy. *J Trauma Acute Care Surg* (2014) **77**:709–15. doi:10.1097/TA.0000000000000445
166. Corser-Jensen CE, Goodell DJ, Freund RK, Serbedzija P, Murphy RC, Farias SE, et al. Blocking leukotriene synthesis attenuates the pathophysiology of traumatic brain injury and associated cognitive deficits. *Exp Neurol* (2014) **256**:7–16. doi:10.1016/j.expneurol.2014.03.008
167. Heard SO, Fink MP, Gamelli RL, Solomkin JS, Joshi M, Trask AL, et al. Effect of prophylactic administration of recombinant human granulocyte colony-stimulating factor (filgrastim) on the frequency of nosocomial infections in patients with acute traumatic brain injury or cerebral hemorrhage. The Filgrastim Study Group. *Crit Care Med* (1998) **26**:748–54. doi:10.1097/00003246-199804000-00027
168. Wong CH, Jenne CN, Lee WY, Léger C, Kubes P. Functional innervation of hepatic iNKT cells is immunosuppressive following stroke. *Science* (2011) **334**:101–5. doi:10.1126/science.1210301
169. Gardner JC, Noel JG, Nikolaidis NM, Karns R, Aronow BJ, Ogle CK, et al. G-CSF drives a posttraumatic immune program that protects the host from infection. *J Immunol* (2014) **192**:2405–17. doi:10.4049/jimmunol.1302752
170. Kumagai T, Takeyama N, Yabuki T, Harada M, Miki Y, Kanou H, et al. Apheresis of activated leukocytes with an immobilized polymyxin B filter in patients with septic shock. *Shock* (2010) **34**:461–6. doi:10.1097/SHK.0b013e3181e14ca0

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2015 Hazeldine, Lord and Belli. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.